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Development and Application of Ribose Oxidation Sequencing (RibOxi-seq) 
Yinzhou Zhu, PhD 
University of Connecticut, 2018 
In eukaryotes, a number of RNA sites are modified by 2’-O methylation (2’-OMe). Such editing 
is mostly guided by BoxC/D class small nucleolar RNAs (snoRNAs). These snoRNAs direct 
methylation via complementary RNA-RNA interactions. 2’-OMe has so far been shown to be 
present in rRNAs, tRNAs and some small RNAs and has been implicated in ribosome maturation 
and translational circuitries. A substantial portion of known methylated sites in rRNA lie in close 
proximity to ribosome functional sites such as regions around the peptidyl transferase center. It is 
not yet clear whether many mRNAs might possess internal 2’-OMe sites. It is therefore 
important to characterize 2’-OMe landscapes. We have developed a novel method for the highly 
accurate and transcriptome-wide detection of 2’-OMe sites. The core principle of this method is 
to randomly digest RNAs to expose 2’-OMe sites at the 3’-ends of digested RNA fragments. 
Next, an oxidation step using sodium periodate destroys all fragment-3’-ends except those that 
are 2’-O methylated. Only these oxidation-resistant fragments are available for linker ligation 
and subsequent sequencing library preparation. We have applied our new method to the study of 
ribose methylation in both Trypanosoma brucei and Mus musculus liver, and successfully 
obtained rRNA 2’-OMe profiles for both organisms. Our sequencing data strongly support 
experimentally validated known sites, while providing several candidates of novel sites, as well 
as evidence for differential methylation. In conclusion, our method is able to reliably identify 2’-
OMe sites in a high-throughput manner. We are also interested in using the method to investigate 
potential mRNA internal sites, the targets of “orphan” snoRNAs, which have no currently known 
targets. 
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Chapter I 
Introduction 
Since establishment of the foundations of molecular biology in the mid-1900s, additional 
modes of gene regulation, which operate beyond the routes of information flow described in the 
original central dogma, have been discovered. Layers of complexity to the seemingly simple 
sequences of bidirectional information transfer from DNA to RNA messages, as well as 
unidirectional translation from RNA molecules to proteins has been added. While Francis 
Crick’s central dogma of molecular biology remains technically valid, the interconnections 
between these three biomolecules have transcended generalization that the conventional 
pathways of information flow. With progress made in the past few decades, we have come to 
establish a more robust representation of cellular networks, which newly integrates 
transcriptional and post-transcriptional regulation networks. These two aspects specifically, have 
grown exponentially partially due to breakthroughs in high-throughput sequencing. Numbers of 
novel non-coding RNAs such as long non-coding RNAs (lncRNAs) have been identified and 
functionally characterized, while micro RNAs (miRNAs), small nuclear RNAs (snRNAs), 
double strand RNA (dsRNA) etc. repertoires have been greatly expanded. More recently, 
epigenetic modification and epitranscriptomic modification studies have garnered considerable 
interest and momentum among the scientific field due to their significant implications in 
transcriptional and post-transcription regulation respectively. Epitranscriptomics, while 
significantly younger than most other fields, encompasses RNA modifications that have been 
known for a very long time. The evolution of collective knowledge of each known RNA 
modification, which I will discuss in greater details later in the current chapter, suggests 
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increasing scientific realization that these modifications, albeit ‘old’, might still possess 
important and novel insights into biological processes and regulation. 
A. Emergence of epitranscriptomics. 
Epigenetics. In 1906, when William Bateson first referenced very little-known Principals of 
Heredity written by Gregor Mendel, the era of modern genetics began with study of monogenic 
traits, or in other words: Mendelian traits. The inheritance unit of the modern genetics is defined 
by ‘gene’, which was introduced by Danish botanist Wilhelm Johannsen, where disparities 
between copies of a single gene are inheritable and contributes to trait differential displayed on 
different individuals within the same organism (Johannsen 1905). Later, contrary to the classic 
mendelian inheritance, the patterns of inheritance for many traits were discovered to follow no 
particular criteria; some traits seemingly mapped to only single genes that violate Mendelian 
rules, or traits having unexplained inheritance plasticity, giving rise to the idea of non-Mendelian 
inheritance. Studies have then established as complex traits, where multiple genes, sex-linked 
traits or incomplete dominance/codominance come into play. (reviewed in Correns 1937, Kowles 
2001, van Heyningen 2004, Cuzin 2013). With advances in biological sciences and technology, 
genetics now deals with finer resolution. We are now looking at genes under single nucleotide 
level and studying how change in bases affect gene expression levels, thus affecting the 
phenotypes of cell types, organs and ultimately organisms. Although the early models of 
inheritance still apply, they fail to account for inheritable traits or gene expression level changes 
not associated with changes in actual DNA sequences. It was not until 1942, when Waddington 
showed inheritable characteristics of Drosophila reacting to environmental stimuli, the study of 
epigenetics (“above” genetics) was proposed (Waddington 1942). Subsequently, mechanisms 
such as DNA methylation, in the form of 5-methylcytosine (m5C), was shown to regulate vital 
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cellular processes including X inactivation, and differentiation related gene expression levels 
(reviewed in Felsenfeld 2007). Both DNA and chromatin methylation and demethylation since 
then been implicated in the mechanism of epigenetics and incorporated into the field of study, 
and epigenetics deals with a collection of modifiers that modulate gene expressions without 
changing nucleotide base identity. These epigenetic modifications are categorized into several 
types including DNA (mainly in the form of methylation) and histone (methylation, acetylation 
and phosphorylation) modifications, each with their own sets of modifying enzymes (reviewed in 
Gardner et al. 2011, Bird 2002). The growth of the epigenetics field, especially for DNA 
modifications, was accelerated with the advent of the next generation sequencing technologies 
(NGS), which made high-throughput identification available through combining NGS and 
bisulfite treatment. Such breakthroughs allowed us to further the study of the field, which leading 
to our current expansive insights into epigenetic regulatory networks that are involved in not 
only basic concept of inheritance, but also in pathology and oncology of various disorders 
(reviewed in Basse & Arock 2015, Mummaneni & Shord 2014, Ordog et al. 2012). 
Epitranscriptomics. Similar to DNA, RNA transcripts are replete with chemical 
modifications. Unlike epigenetics, which revolves around just a few types of marks, the RNA 
modification repertoire is highly diverse in terms of chemical properties (reviewed in He 2010). 
Up until the early 2010s, most important known RNA modifications to date were on tRNAs, 
small RNAs and rRNAs, although most of these modifications have been chemically 
characterized for decades, how they function was largely unclear (Motorin & Grosjean 1998). 
While the most recent curation has revealed approximately 170 different types of RNA 
modifications, novel modifications are still being actively discovered and added. Also, the 
estimated number of sites across the transcriptome could be far more than just a few hundreds 
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(Boccaletto et al. 2018). Contrary to epigenetic marks, whose regulatory roles on gene 
expressions are carried out by altering accessibility of genomic regions, RNA modifications have 
been traditionally regarded as structural features that affect transcript rigidity and stability (Sloan 
et al. 2017). While the collective significance of them is still being actively pursued, regulatory 
functions have been ascribed for some RNA editing, including Apobec3 induced C to U 
deamination, ADAR induced A-to-I editing, and N6-methyladenosine (m6A). The collective 
evidence and evolution of methods to study RNA modifications have thus resulted in the 
emergence of the field of transcriptomics, where chemical changes/additions to the RNA that 
confer additional layers of biological functions are examined. Most of the modifications already 
known for decades might not seem appealing when looked at through conventional methods, but 
when coupled with recent advancements in NGS technologies, these modifications are garnering 
renewed interest and optimism through the field of epitranscriptomics as a result of continuing 
discoveries of their novel roles. 
RNA base methylations. Modifications on RNA transcripts form a highly distinct set. The 
modifications can happen in a variety of ways. For example, a methyl group can be added to an 
adenosine at different positions on the nitrogenous base to form 1-methyladenosine (m1A), 2-
methyladenosine (m2A) etc (Dunn 1961, Starr & Fefferman 1964). A different base such as 
cytosine, can also be modified with the same chemical group; In addition to structurally 
distinctive modifications with the same chemical group, more than 50 different chemical 
moieties are contained in the set including thiols, esters etc; all modifications but a few, which 
occur on the ribose of a nucleotide (2’-O-methyl, 2’-O-ADP etc.), are found on the nitrogenous 
base of the nucleotides (base methylation, reviewed in Wang & He 2014). Very interestingly, 
RNA such as mRNA and tRNA can contain more than 50 different base modifications, while 17 
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occur on eukaryotic rRNA alone. Because many of them have been extensively characterized 
across different species spanning all 3 domains of life, phylogenetic studies have been possible, 
revealing that RNA modifications are conserved (Cantara et al. 2011, and references therein). A 
table of prevalent modifications summarized from Cantara et al. (2011) and Pietro et al. (2017) is 
provided here (Table 1). Although the number of modifications is large, there is a core subset of 
them that have been focused on by researchers due to functional importance, prevalence of the 
modification and overall distribution patterns. To have an accurate reflection of the recent status 
of the field of epitranscriptomic studies, I will focus on the following RNA modifications: N6-
methyladenosine (m6A), 5-methylcytosine (RNA: m5C), N1-methyladenosine (m1A), Adenosine 
to Inosine editing (A-to-I), pseudouridine (Ψ), and 2’-O-methylation (2’-OMe).  
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Table 1. List of major RNA modifications for Archaea, Bacteria and Eukarya. 
Symbol Common Name Found on: 
m3Um 3,2′-O-dimethyluridine mRNA 
m2,2,7G N2, N2,7-trimethylguanosine mRNA,snRNA 
m6Am N6,2′-O-dimethyladenosine mRNA,snRNA 
m2,2G N2, N2-dimethylguanosine rRNA 
m4C N4-methylcytidine rRNA 
m1acp3Y 1-methyl-3-(3-amino-3-carboxypropyl) 
pseudouridine 
rRNA 
m3Y 3-methylpseudouridine rRNA 
m3U 3-methyluridine rRNA 
cm5U 5-carboxymethyluridine rRNA 
hm5C 5-hydroxymethylcytidine rRNA 
m8A 8-methyladenosine rRNA 
Nm 2′-O-methyladenosine rRNA,tRNA,snRNA 
 
2′-O-methylcytidine 
 
2′-O-methylguanosine 
 
2′-O-methylinosine 
 
2′-O-methylpseudouridine 
 
2′-O-methyluridine 
m6,6Am N6, N6,2′-O-trimethyladenosine rRNA,mRNA 
m2G N2-methylguanosine rRNA,snRNA 
m1A 1-methyladenosine rRNA,tRNA 
m1G 1-methylguanosine rRNA,tRNA 
m1Y 1-methylpseudouridine rRNA,tRNA 
m2A 2-methyladenosine rRNA,tRNA 
acp3U 3-(3-amino-3-carboxypropyl) uridine rRNA,tRNA 
m3C 3-methylcytidine rRNA,tRNA 
m5Um 5,2′-O-dimethyluridine rRNA,tRNA 
m4,4Cm N4, N4,2′-O-trimethylcytidine rRNA,tRNA 
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ac4Cm N4-acetyl-2′-O-methylcytidine rRNA,tRNA 
ac4C N4-acetylcytidine rRNA,tRNA 
m7G 7-methylguanosine rRNA,tRNA,mRNA 
m6A N6-methyladenosine rRNA,tRNA,mRNA,snRNA 
  pseudouridine rRNA,tRNA,mRNA,snRNA 
D Dihydrouridine rRNA,tRNA,snRNA 
m1Nm 1,2′-O-dimethyladenosine tRNA 
 
1,2′-O-dimethylguanosine 
 
1,2′-O-dimethylinosine 
m1I 1-methylinosine tRNA 
msms2i6A 2- methylthiomethylenethio-N6-isopentenyl-
adenosine 
tRNA 
k2C 2-lysidine tRNA 
ms2io6A 2-methylthio-N6-(cis-hydroxyisopentenyl) 
adenosine 
tRNA 
ms2hn6A 2-methylthio-N6-
hydroxynorvalylcarbamoyladenosine 
tRNA 
ms2m6A 2-methylthio-N6-methyladenosine tRNA 
ms2t6A 2-methylthio-N6-threonylcarbamoyladenosine tRNA 
s2Um 2-thio-2′-O-methyluridine tRNA 
s2C 2-thiocytidine tRNA 
s2U 2-thiouridine tRNA 
Ar(p) 2′-O-ribosyladenosine (phosphate) tRNA 
Gr(p) 2′-O-ribosylguanosine (phosphate) tRNA 
imG-14 4-demethylwyosine tRNA 
s4U 4-thiouridine tRNA 
m5Cm 5,2′-O-dimethylcytidine tRNA 
mchm5Um 5-(carboxyhydroxymethyl) -2′-O-
methyluridine methyl ester 
tRNA 
inm5s2U 5-(isopentenylaminomethyl) -2-thiouridine tRNA 
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inm5Um 5-(isopentenylaminomethyl)-2′-O-
methyluridine 
tRNA 
inm5U 5-(isopentenylaminomethyl)uridine tRNA 
nm5se2U 5-aminomethyl-2-selenouridine tRNA 
nm5s2U 5-aminomethyl-2-thiouridine tRNA 
ncm5Um 5-carbamoylmethyl-2′-O-methyluridine tRNA 
ncm5U 5-carbamoylmethyluridine tRNA 
cmnm5s2U 5-carboxymethylaminomethyl-2-thiouridine tRNA 
cmnm5Um 5-carboxymethylaminomethyl-2′-O-
methyluridine 
tRNA 
cmnm5U 5-carboxymethylaminomethyluridine tRNA 
f5Cm 5-formyl-2′-O-methylcytidine tRNA 
f5C 5-formylcytidine tRNA 
ho5U 5-hydroxyuridine tRNA 
mcm5s2U 5-methoxycarbonylmethyl-2-thiouridine tRNA 
mcm5Um 5-methoxycarbonylmethyl-2′-O-methyluridine tRNA 
mcm5U 5-methoxycarbonylmethyluridine tRNA 
mo5U 5-methoxyuridine tRNA 
m5s2U 5-methyl-2-thiouridine tRNA 
mnm5se2U 5-methylaminomethyl-2-selenouridine tRNA 
mnm5s2U 5-methylaminomethyl-2-thiouridine tRNA 
mnm5U 5-methylaminomethyluridine tRNA 
tm5s2U 5-taurinomethyl-2-thiouridine tRNA 
tm5U 5-taurinomethyluridine tRNA 
m2Gm N2,2′-O-dimethylguanosine tRNA 
m2,7Gm N2,7,2′-O-trimethylguanosine tRNA 
m2,2Gm N2, N2,2′-O-trimethylguanosine tRNA 
io6A N6-(cis-hydroxyisopentenyl) adenosine tRNA 
ac6A N6-acetyladenosine tRNA 
g6A N6-glycinylcarbamoyladenosine tRNA 
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hn6A N6-hydroxynorvalylcarbamoyladenosine tRNA 
i6A N6-isopentenyladenosine tRNA 
m6t6A N6-methyl-N6-threonylcarbamoyladenosine tRNA 
t6A N6-threonylcarbamoyladenosine tRNA 
OHyW hydroxywybutosine tRNA 
OHyWy methylated undermodified hydroxywybutosine tRNA 
mimG methylwyosine tRNA 
o2yW peroxywybutosine tRNA 
cmo5U uridine 5-oxyacetic acid tRNA 
mcmo5U uridine 5-oxyacetic acid methyl ester tRNA 
imG wyosine tRNA 
Q queuosine tRNA 
oQ epoxyqueuosine tRNA 
galQ galactosyl-queuosine tRNA 
manQ mannosyl-queuosine tRNA 
preQ0 7-cyano-7-deazaguanosine tRNA 
preQ1 7-aminomethyl-7-deazaguanosine tRNA 
I inosine tRNA, mRNA 
m5C 5-methylcytidine tRNA, mRNA 
m2,7G N2,7-dimethylguanosine tRNA, mRNA 
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M6A is the most abundant base methylation epitranscriptomic mark known to date. This 
modification was originally discovered in tRNAs rRNAs and poly-A RNA fractions (Bokar et al. 
1997). M6A was originally thought to modulate tRNA and rRNA folding structures and 
stabilities due to its base pairing weakening properties. Although in vitro biochemical techniques 
in earlier studies that used synthetic oligos, as well as C14 methionine labeling techniques, gave 
insights of the potential functions of the modifications, the physiological relevance of these in 
vitro results was not established (reviewed in Saletore et al. 2012). At the same time, mapping 
sites had proven to be difficult and laborious using low-throughput HPLC or thin-layer 
chromatography; most frustratingly, it was hard to determine where to look in longer transcripts 
such as rRNAs and mRNAs (reviewed in Zhao et al. 2016). Thus, progress on the 5-decade-old 
modification remained stagnant. However, emergence of NGS technology brought capability of 
high-throughput DNA sequencing, which was then developed to also support RNA sequencing. 
It did not take long before the next gen RNA sequencing technology was adapted for high-
throughput m6A detection. Dominissini et al. (2012) and Meyer et al. (2012) took advantage of 
the existence of m6A antibodies to immunoprecipitate RNAs with the modification followed by 
subjecting the RNA fragments to RNA sequencing procedures after fragmentation. Subsequent 
alignment of the sequenced fragments would then allow assigning intervals where RNAs are 
modified down to 25-100 base pair resolution transcriptome-wide. Due to the nature of the 
immunoprecipitation, it was not possible to obtain single-base resolution. However, this 
experimental design allowed researchers to finally generate m6A profiles, to perform association 
studies, and to eventually narrow in on genes/pathways of interest followed by validation using 
traditional methods. Since then a number of biological pathways involving the modification have 
characterized, for example the findings that: naturally occurring modifications with m6A affect 
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levels of pluripotency-promoting transcripts through transcriptional regulation. Thus disrupting 
steady-state demethylation alters embryonic stem cell (ESC) transition from the naïve to the 
primed state, while hyper demethylation contributes to tumorigenesis (Cui et al. 2017); m6A , 
highly enriched in the brain, can also regulate splicing, and is involved in brain development, sex 
determination in Drosophila via alternative splicing, as well as human x chromosome 
inactivation(Lence et al. 2016, Patil et al. 2016, Xiao et al. 2016); and the modification has also 
been recently shown to directly impact mRNA translation elongation through altered base 
pairing thermal dynamics with tRNAs (Choi et al. 2016). Owing to the now expanded lists of 
m6A writers (methyltransferases), erasers (demethylases), readers (m6A binding proteins) and 
clear biological functions characterized (RNA stability, signaling and splicing), m6A is the 
epitome of the field of epitranscriptomics with constructions of m6A landscapes playing vital 
roles in discoveries/validations of specific concepts and results (Figure 1, reviewed in Niu et al. 
2012, Zhao et al. 2016).  
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Figure 1. Functional Roles of m6A 
A simple diagram summarizing m6A mediated functions. Black arrows represent functions mediated 
under nominal conditions. The green arrow represents methylation/demethylation imbalance, resulting in 
decrease in overall methylation level. 
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Diverse functions of RNA modification by means of N6-methyladensine 
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Both m5C and m1A are less well characterized epitranscriptomic marks compared to m6A. 
Similar to m6A, m5C and m1A are RNA modifications described many years ago (Yuki & 
Fujiwara 1976, Hong et al. 1997). Like its sibling DNA m5C, RNA m5C had been shown to be 
potentially present on polyadenylated RNA decades ago, when it was discovered; although 
possessing almost the same chemical properties as m5C in DNA, the biological functions of 
RNA m5C’s remain largely elusive (reviewed in Oerum et al. 2017). Unlike m6A, which has 
been extensively mapped across different RNAs, cell types and species, m5C has only a few 
available transcriptome wide mapping results available for further study to date. Bisulfite 
sequencing, which is the high-throughput detection method available for both DNA and RNA, 
has been available and became a rather mature detection method (Schaefer et al. 2009). Thus, the 
pace of m5C profiling has been picking up recently, and studies have started filling in some gaps 
including: 1) analysis of m5C conservation in plant rRNAs (Burgess et al. 2015); 2) differential 
methylation studies between mouse organs (Johnson et al. 2016); 3) evidence of m5C shaping 
chromatin organization, affecting drug resistance to leukemia(Cheng et al. 2018); and 4) 
correlation of 5hmC, a derivative of m5C, with global modification patterns and glioblastoma 
survival (Amort et al. 2017 and references therein). M1A on the other hand, was identified as a 
novel modification on poly(A)+ RNAs. It was only detected in mRNAs and some long non-
coding RNAs in 2016 after antibody-based IP coupled with NGS was adapted from m6A 
detection method (Dominissini et al. 2016). Realization of the importance of high-throughput 
detection techniques has led to the active development of more methods for its detection and 
mapping (Ritchey et al. 2017). Although, available datasets for both m5C and m1A mainly point 
to structural roles contributing to RNA stability, further probing and validations are required to 
examine whether these two modifications could have similar levels of functions to m6A. We 
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expect to gain more insights as more data are generated from current methods and methods being 
actively developed.  
Guide RNA dependent modifications. m6A, RNA m5C and m1A are added to target RNA 
bases through guidance to specific RNA motifs by other protein components that directly 
recognize the motifs. On the other hand, A-to-I editing and pseudouridylation are guide RNA 
dependent. A-to-I RNA editing is the chemical reaction where adenosine undergone hydrolytic 
deamination by adenosine deaminases that act on RNA (ADAR) protein family members, 
resulting in inosine, which base-pairs with C instead of U and functions genetically and 
biochemically in the cell as guanosine (Polson et al. 1991). This is one of the special cases where 
modification changes the nucleotide identity; however, as the field of epitranscriptomics evolves, 
the definition has been expanded to include modifications confer regulatory functions. And the 
current consensus is that the A-to-I editing can be considered as a type of epitranscriptomic 
change (reviewed in O’Connell 2015). A-to-I editing, which has both nuclear and cytoplasmic 
components, occurs on dsRNAs including sense-anti-sense paired transcripts and 
intramolecularly paired repeat elements such as Alu, SINE and LINE elements; editing sites of 
ADARs were originally discovered through sequence mismatches when comparing genomic 
sequences with cDNA sequences from particular RNA transcripts. ADAR editing has been 
reported to regulate miRNA processing and efficacy in cytoplasm; it has also been shown that 
elicitation of interferon responses against dsRNAs are suppressed by ADAR editing (reviewed in 
Nishikura 2010). It was not until NGS became available that A-to-I editing sites could be 
analyzed on a large scale (reviewed in Nishikura 2016). From past accumulated evidence 
together with recent deep sequencing studies, we now have a more comprehensive understanding 
of the actions of ADAR family proteins. It has been demonstrated from the collective profiles of 
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the editing sites that ADAR proteins exhibit two modes of activity – promiscuous editing and 
site selective editing. As a result of promiscuous editing, a significant portion of the human 
transcriptome has extensive stretches of A to I conversions, with Alu RNAs being the majority. It 
was shown to have vital role in preventing cellular damage from dsRNA mediated innate 
responses. Such function is highly correlated with inhibition of nuclear export of the highly 
edited RNA transcripts into the cytoplasm (reviewed in Nishikura 2010, O’Connell et al. 2015). 
Site-selective mode, on the other hand, pinpoint and modify a small group of adenosines resulted 
from limited imperfect base-pairing of neighboring bases. Such editing mode has been reported 
to occur on several mRNA transcripts, including AMPA receptor subunit GluR-B, K(V) 
potassium channel etc. The editing on the GluR-B, a glutamate gated ion channel, was shown to 
be important for brain functions (Higuchi et al. 1993, Greger et al. 2002, Greger et al. 2003). It 
was also reported that editing on K(V) mRNA is a mechanism of controlling channel inactivation 
(Bhalla et al. 2004).  
ADAR editing is also abundantly enriched during viral infections, such as by Murine 
polyomavirus (MPyV). During infection, overlapping portions of viral RNA concatemers are 
promiscuously edited (Chen & Carmichael 2009, Garren et al. 2015). Consistent with an in vitro 
study, where viral gene expressions were downregulated by editing, the RNA modification can 
have additional role in anti-viral responses (Gu et al.2009). Although such observations indicate 
certain roles the modification play during said biological processes, whether they are the cause or 
result are still being debated and will need to be verified. It is encouraging to see that creatives 
tool have been actively developed for the study of ADAR editing: CRISPR guide RNAs are 
introduced to form double stranded structures with targets, while ADAR is tethered to the dCas9 
for targeted editing (Fukuda et al. 2017). Such strategy would allow generation of related tissue 
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cultures and transgenic mice lines for easier study of the editing under more physiological 
relevant conditions. While we wait for more studies to come out, clinical applications of the 
ADARs are also being explored. 
Recent methodological advancements have also enabled thorough profiling of RNA 
pseudouridylation, which was the first RNA modification discovered and which results in the 
conversion of uridine to pseudouridine through RNA guided isomerization of the uridine by 
pseudouridine synthase (PUS) (Massenet et al. 1999). Following early discoveries made on 
tRNAs and rRNAs, the high density of this modification was generally believed to be the most 
abundant cellular RNA modification (Cohn and Volkin 1951). The RNA guiding the 
modification is a class of small nucleolar RNA (snoRNA) that possesses RNA motifs called box 
H/ACA motifs. snoRNAs are assembled into ribonucleoprotein particles (snoRNPs) that possess 
both targeting and enzymatic functions. The H and ACA motifs together with neighboring 
sequences determine target RNA sites, while scaffolding proteins and PUS are assembled around 
the boxes (reviewed in Li et al. 2016). Pseudouridylation patterns have been shown to be highly 
conserved in rRNAs, tRNAs and small nuclear RNAs (snRNAs). Pseudouridines have been 
considered to mainly contribute to rRNA folding and occur in a conserved pattern around the 
peptidyl transferase center (ptc) -interacting region (reviewed in Ge & Yu 2013). Pseudouridine, 
together with 2’-O methylation both utilize the snoRNA machinery. Although two modifications 
are chemically different, they conventionally seem to have similar functions. Importantly, a 
transcriptome-wide deep sequencing detection method (Pseudo-seq) using a chemical modifier 
specific to pseudouridine was recently developed to identify pseudouridines at single-base 
resolution (Schwartz et al. 2014, Carlile et al. 2014). Since then, additional novel 
pseudouridylation sites in both non-coding RNAs and mRNAs have been identified, at the same 
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time, this could be where pseudouridylation and 2’-O methylation diverge. Besides expanding 
the pseudouridylation landscape, pseudouridine profiles generated so far has shown some 
potential correlations between the modification and diseases. For example, normal and 
dyskeratosis congenita patient pseudouridylation patterns were profiled and results suggested 
strong enrichment and differential modification on telomerase RNA component (TERC), which 
is implicated in the pathology (reviewed in Zhao & He 2015). Li et al. (2016) have noted a 
renewed interest and speculated the potential role of pseudouridine in gene regulation. 
Although there are currently a number of other examples of RNA modification, such as C-to-
U editing by APOBEC family protein members (which have also been identified as DNA 
modifiers), I feel the critical point to emphasize is the importance of development of new 
methodologies that allow the of biological processes/components and discoveries of new 
applications has been properly expressed. In the rest of this thesis, I will focus on a single RNA 
modification, 2’-O-methylation.  
B. Ribose methylation/2’-O-methylation. 
Mechanisms of snoRNA guided 2’-O-methylation. 2’-O-methylation is the addition of a 
methyl group to the 2’-O-position of a nucleotide sugar backbone-ribose-, which is why it is also 
referred to as ribose methylation (Figure 2A). Deposition of the modification is an RNA-guided 
event similar to that of the RNA pseudouridylation, where snoRNAs play a central role in the 
process. Contrary to pseudouridylation, ribose methylation is guided by snoRNAs that contain 
box C/Ds instead of box H/ACAs, despite the existence of rare snoRNAs that can guide both 2’-
O-methylation and pseudouridylation.  
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Figure 2. Box C/D snoRNA guided 2’-O-methylation and Box C/D snoRNP biogenesis 
(A) A simplified diagram for box C/D snoRNA guided 2’-O-methylation. The addition of one methyl 
group, which is highlighted in red on the bottom panel, to the ribose 2’-O position is carried out by box 
C/D snoRNPs.  
(B) Box C/D snoRNP biogenesis for human is summarized here. snoRNA biogenesis for other eukaryotes 
and Archaea undergo same procedures, while Nop56, Nop58, 15.5k and fibrillarin are replaced with other 
protein homologs. Box H/ACA snoRNPs biogenesis also share the same mechanism with box C/D 
snoRNPs with the exception of recruiting different scaffolding and catalytic proteins.  
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Box C/D snoRNAs (H/ACA biogenesis is similar) are processed inside the nucleus from 
intronic regions of RNA PolII transcribed host RNAs that undergo splicing. Between steps of 
spliceosome assembly to lariat formation during co-transcriptional splicing of the host RNAs, 
scaffolding proteins 15.5K, Nop58, Nop56 and the methyltransferase Fibillarin become 
associated with the C/D boxes (reviewed in Kiss 2006). When the lariat is debranched, 
exonuclease degradation occurs to eliminate the entire intron except for the snoRNA portion 
protected by the bound proteins, forming functional snoRNPs (Figure 2B, Baserga et al. 1991, 
Hirose et al. 2003). Some snoRNPs permanently localize to Cajal bodies and are subsequently 
named small Cajal body-specific RNPs (scaRNPs). These RNPs carry out modifications of small 
nuclear RNAs (snRNAs). Some others transiently localize to Cajal bodies before eventual 
trafficking into the nucleolus, while the rest localize directly to the nucleolus (Kiss et al. 2006). 
These RNPs directly participate in the maturation of ribosomal RNAs by means of extensive 
methylation prior to the assembly of ribosomal subunits and processed rRNAs inside the 
nucleolus (Figure 3, reviewed in Pelletier et al. 2017). It has been known that tRNAs are also 
internally methylated, while miRNAs are 2’-O-methylated at their 3’ ends. These RNAs are 
methylated through site-specific protein-mediated processes (reviewed in Clouet-D’Orval et al. 
2005). Interestingly, while there is no evidence indicating eukaryotic tRNA and miRNA 
methylation through snoRNPs, both protein-mediated and guide RNA-dependent mechanisms 
occur on Archaea tRNAs (Renalier et al. 2005). 
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Figure 3. Box C/D snoRNP trafficking and its roles in RNA processing 
Box C/D snoRNPs either directly localize to nucleolus, or transiently travel to cajal bodies before 
localization to nucleolus. Box C/D snoRNPs carry out 2’-O-methylation on pre-rRNAs, which is a 
necessary step for rRNA maturation and ribosome biogenesis. The snoRNPs also 2;-O-methylate snRNAs 
inside Cajal bodies. 
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Box C/D snoRNAs fold into stem loop structures but retain spacers of at least 12-bp on each 
side of the stem loop (between Box C and Box D’, and between Box C’ and Box D), and these 
anneal to target substrates; the spacer sequences form a maximum of 10-bp complementary base 
pairs with targets in Archaea, while lengths of duplexes are rather variable in eukaryotes (Kiss  
2001, Yang et al. 2016). In most cases, methylation, catalyzed by fibrillarin, occurs at the 4th or 
5th base in the base pairing region upstream of box D and/or D’, and mismatches around the 
region abolish methylation activity (Figure 4, Cavaillé, & Bachellerie 1998). 2’-OMes densely 
populate rRNAs and possibly other RNAs, necessitating a number of different snoRNAs guiding 
the extensive modifications. Interestingly, cases where one snoRNA can mediate the methylation 
of multiple sites in human, such as U24 snoRNA on 28S rRNA base location 2350 and 2364, 
have been observed possibly due the repetitive nature of some regions of rRNAs. Not 
surprisingly, box H/ACA snoRNAs can also display such a property including ACA17 snoRNA, 
which guides pseudouridylation on 28S rRNA at both base position 4678 and 4956. In some rare 
cases, different snoRNAs can target the same site. Taking U51 and U32A for example, each can 
target base position 1523 on 28S rRNA, but at the same time, each has a different target at  a 
different position (https://www-snorna.biotoul.fr/browse.php?sno=CDBox). Whether this 
redundancy is selected for during evolution or just a coincidental remains unclear. It is possible 
that 2’-OMe on 28S rRNA position 1523 contributes more either structurally or functionally, 
studies mutating the site or probing structural properties might provide some answers. 
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Figure 4. Typical box C/D snoRNA guide and target 
Box C/D snoRNA sequences immediately upstream of box D or box D’ base pair with target RNA to 
form duplex structures. In most cases, either the 4th or the 5th base upstream of the two boxes is 
methylated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
 
 
 
 
 
 
 
 
 
 
27 
 
Additional observed snoRNA properties. The snoRNA structures in general follow the rule 
shown in Figure 4, but there are a few exceptions. U85 scaRNA was the first scaRNA discovered 
as a box C/D and box H/ACA hybrid. This composite scaRNA seems to be functional as 
overexpression of a snRNA chimera has shown correct 2’-O-methylation and pseudouridylation 
(Jády and Kiss 2001). Since then, 3 more composite scaRNAs, as well as dual boxC/D and dual 
box H/ACA snoRNAs have been identified. These special snoRNAs (scaRNAs) were manually 
curated due to highly altered secondary structures and folding dynamics. Although the number of 
these snoRNAs are quite low (13), they are fairly conserved across species dating back to early 
vertebrates (Lestrade 2006, Marz et al. 2011). Therefore, further investigation might provide 
insights on the importance of conservation in these RNAs. 
Although the number of curated known and predicted box C/D snoRNAs in human alone 
amounts to more than 250 in human and close to 350 in mouse, a significant portion of them 
have no known methylation targets; conversely, yeast possesses much less snoRNAs and 
majority of them are well known, most likely due to its inherently small genome (Table 2). 
Compared to rRNAs, which are abundantly expressed and where matching 2’-O-methylation 
guide snoRNAs have been identified, finding the targets of the snoRNAs with no obvious 
complementarity to rRNAs has proven to be difficult (Jády & Kiss 2000). The major hurdle 
presented to the community has been that each base pairing sequence between a snoRNA guide 
and its target is so short. Validating predicted pairs is not feasible without already having a list of 
high confidence modification sites for cross checking, as predictions based on base pairing alone 
can generate hundreds or even thousands of potential methylation sites. Thus, these snoRNAs 
without known targets are designated “orphan” snoRNAs (Jorjani et al 2016).  
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 Table 2. Summary of snoRNAs from curated database. 
 
 
 
 
 
 
snoRNA list summarized from snoRNA Orthological Gene Database (snoopy): 
http://snoopy.med.miyazaki-u.ac.jp/snorna_db.cgi (Yoshihama & Kenmochi 2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
Species 
Total # of known 
and predicted C/D 
snoRNAs 
# with rRNA 
targets 
# with snRNA 
targets 
# with unknown 
targets 
Human  213 129 5 79 
Mouse 327 132 5 193 
Yeast 47 45 - 2 
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Interestingly, a number of snoRNAs of both box C/D and box H/ACA types, and both orphan 
and non-orphan have also been found to be processed into miRNA like structures and possess 
miRNA activities. Some of these snoRNA derived miRNAs such as SNORD78-miRNAs have 
been reported to be correlated with non-small- cell lung cancer, indicating potential functions 
outside of the conventional scope (Saraiya & Wang 2008, Ender et al. 2008, Scott et al. 2009, 
Brameier et al.2011). Although it is possible that the effects mentioned are purely contributed 
from miRNA forms of these snoRNAs, it has not been explored whether potential 2’-O-
methylations are carried out by these snoRNAs, whether the methylation levels also correlate 
with pathology of said cancers. In addition, snoRNAs are found to be part of two types of 
unusual RNAs: sno-lncRNAs and SPA-ncRNAs (Wu et al. 2016, Yin et al. 2012). Functions 
claimed in these studies attempt to explain Prader Willi syndrome in a way that complements our 
hypothesis that 2’-O-methylation plays an important or even central role, and they will be briefly 
discussed in a later section.  
Mechanism of RNA guide-independent 2’-O-methylation. As mentioned above, ribose 
methylation in eukaryotes mainly employs a snoRNA independent mechanism for tRNAs and 
miRNAs. For tRNAs, most of the well characterized methyltransferases, termed Trm(s), were 
discovered in bacteria and yeast. Trms belong to a class of S-adenosyl-L-methionine (AdoMet)-
dependent enzymes in the SPOUT superfamily (Tkaczuk et al. 2007 and references therein). 
Currently, Trm7 has been identified to directly deposit methyl group at 2’-O positions on bases 
of tRNA-Phe, tRNA-Trp, and tRNA-Leu in yeast. FTSJ1 has since then been reported to be 
human homolog to the Trm7 (Pintard et al. 2002, Guy et al. 2017, Somme et al. 2014, Bourgeois 
et al. 2017 and references therein).  Hen1, a helix-loop-helix (HLH) family transcription factor 
harboring both a dsRNA binding domain, as well as a 2’-O-methyltransferase domain, is another 
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2’-O-methyltransferase ubiquitously expressed (Begley et al. 1992, Yu et al. 2005). Owing to 
flexibility in its RNA binding domain, Hen1 is able to bind to and catalyze 2’-O-methylation of 
the 3’- ends of piRNAs and miRNAs, whose precursors exist in partially double stranded forms. 
Similar to Trm7, Hen1 is highly conserved and homologs are found across species within 
eukaryotes (Brown et al. 1992, Kirino& Mourelatos 2007, Saito et al. 2007).  
In yeast and mammals, 2’-O-methylation of mRNA cap structures is also carried out through 
non-guide-RNA pathway. mRNA 5’-capping is an important process for mRNA biogenesis. 
Successful capping protects RNA transcripts from 5’to 3’ exonuclease degradation, enables 
nuclear export and is required for most translation initiation events in the cytoplasm. A typical 
5’-cap structure consists of cap0, cap1 and cap2 components, where the inverted 7-
methylaguanisime (cap0) is linked to two cap1-cap2, which are the first and second transcribed 
bases, through triphosphate linkage. (reviewed in Smietanski et al. 2014 & Hocine et al. 2010).  
FTSJD1 and FTSJD2, were identified to be the methyltransferases for mRNA cap1 and cap2 
through methyltransferase domain homology to tRNA and rRNA 2’-O-methyltransferases (Trm7 
and fibrillarin). As part of the final cap structure, virtually all mRNAs are methylated at cap0 and 
cap1, while only a subset of the mRNAs contains cap2 2’-O-methylation (Furuichi et al. 1975, 
Werner et al. 2011).  
Functions of ribose 2’-O-methylation. The translation machinery is one of the most vital 
components of biological units across all domains of life. In mammals, mRNA translation is 
carried out by ribosomes in the cytoplasm with the help of tRNAs in decoding mRNAs. The 
ribosomal complex is responsible for synthesis of all cellular proteins. Even ‘lifeless’ viruses rely 
host ribosomal machinery for propagation. Due to the important nature of the translation, the 
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upstream and downstream processes are heavily regulated as evidenced by plethora of 
transcriptional and post transcriptional regulation pathways. (reviewed in Walsh & Mohr 2011).  
As one of best characterized RNA species, human rRNA contains at least 150 2’-O-
methylated bases. Although known methylation patterns on rRNA are generally conserved from 
yeast to human, mostly occurring in regions close to the peptidyl transferase center (PTC), 
functions of these epitranscriptomic marks remain inconclusive (Decatur & Fournier 2002). 
Several studies attempting to elucidate exact functions of the modification have resulted in 
underwhelming results. Serial or aggregated deletions and or mutations of tens of box C/D 
snoRNA guides that targets methylation sites near core region of rRNA yielded mild phenotypes 
and growth defects (Esguerra et al. 2008 and references therein). Experiments where multiple 
modification sites were unmethylated seemed to have produced slightly stronger phenotypes 
albeit mild nonetheless; similarly, snRNAs, which also possess extensive and conserved 2’-O-
methylation patterns, have been shown to have mild defects when snoRNAs targeting them are 
manipulated (Karijolich & Yu 2007 and references therein). Taken together, these data suggest 
that 2’-O-methylation on rRNAs and snRNAs might function as structural enhancement features 
that contribute to RNA transcript rigidity without individually being essential (reviewed in Sloan 
et al. 2017,). Surprisingly, homozygous knock out of fibrillarin, the 2-O methyltransferase 
component of the box C/D snoRNPs, proved to be lethal in yeast and resulted in development 
lethality in mouse embryos; meanwhile, heterozygous KO of the gene had no noticeable 
phenotype, suggesting a strong tolerance for protein level fluctuations; interestingly the same 
study showed that correct localizations of the snoRNAs are also disrupted under homozygous 
KO conditions, consistent with the requirement of the methyltransferase binding for snoRNA 
maturation (Newton et al. 2003). Although not reported in the publication, there has been no 
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available fibrillarin KO cell line or conditional fibrillarin KO mouse, which might signify that 
depletion of fibrillarin is also lethal even later in developmental stages. Such effects, contrary to 
the putative function of the methylation, suggest that there are two potential models. First, 
snoRNAs are structurally essential. Depleting fibrillarin depletes snoRNAs and the cumulative 
effect of elimination of all 2’-O methylation is lethal. Second, at least some specific ribose 
modification(s) is/are functionally essential, requiring catalytic activity of fibrillarin, and there 
are site(s) not known associated with lethal effect resulted from fibrillarin knockout (Figure 5). 
For 2’-O-methylation, although it is highly likely that it contributes to RNA structural stability, 
as well as influences folding as evidenced by its distribution patterns in different RNA species 
and studies performed on rRNA biochemical properties (Dennis et al. 2015, Satoh et al. 2000), 
we cannot disregard the possibility that the modification has additional functions and is more 
broadly distributed over the transcriptome at the same time.  
 
 
 
 
 
 
 
 
 
33 
 
Figure 5. Models for potential roles of 2’-O-methylation. 
See text for details. 
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RNA-independent ribose methylation biochemically achieves the same goal as snoRNA 
guide methylation in eukaryotes and Archaea, however, their substrates are largely different. The 
strong conservation of various 2’-O-methylation mechanisms suggests that having the 
modification is likely conferring some type(s) of evolutionary advantage. It has been known that 
there exist everlasting power struggles between organisms, such as higher eukaryotes against 
viruses, throughout the evolutionary process. As viruses evolve, other organisms have to keep up 
the pace to fend off potential viral infection. Such back and forth competition has shaped our 
immune mechanisms and viral infection strategies. 2’-OMes at mRNA 5’-cap in higher 
eukaryotes and some viral transcripts seem to be one hallmark of such a process. Hosts utilize 2’-
OMe on the 5’-cap to distinguish self from non-self since mRNA from viruses that replicate in 
the cytoplasm are modified differently. The lack of 2’-OMe at cap structures can elicit interferon 
induced responses, thus attenuating viral replication. Interestingly, some viruses encode their 
own 2’-O-methyltransferases, evading such host immunity (Daffis et al. 2010, Hyde & Diamond 
2015, Züst et al. 2011). Further, non-cap internal 2’-OMe was found in falvivirus NS5 
transcripts. The presence of this modification reduced the rate of translation and RNA synthesis, 
which might indicate an alternative strategy to elude host immune system detection (Dong et al. 
2012). A similar strategy has also been found to be exploited by bacteria, where a single specific 
ribose methylation on a bacterial tRNA is enough to antagonize TLR7/8 induced innate 
immunity (Rimbach et al. 2015, Schmitt et al. 2017). In another unusual case associated with 
immunity, a naturally occurring 2’-OMe on human 18S rRNA has been reported to be capable of 
stimulating, not suppressing, the TLR7/8 response pathway (Jung et al. 2015). Although, it is 
unclear whether this methylation event is linked to any potential function, it might be worth 
studying under the scope of autoimmunity.  
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Although current lines of evidence suggest 2’-OMe could be multi-functional, a 
comprehensive description of the consequences of modification is lacking. Taking all available 
findings into consideration, it is clear that we need more data points to make proper 
generalizations. Here are some of the questions we can ask. How strongly do internal 2’-OMes 
of some viruses affect viral life cycles and how widespread, is this mechanism? Is TLR7/8 
activating 2’-OMe only a rare case? Do 2’-OMe functions vary, and by how much, between cell 
types? How variable is 2’-O-methylation on rRNA, and does 2’-O-methylation variability 
correlated with cellular phenotypes? Can RNA-guided methylation occur in the cytoplasm or 
nucleoplasm, instead of only in the nucleolus and Cajal bodies?  
C. Insights into 2’-OMe in humans. 
Despite the observation that snoRNA derived miRNA-like RNAs are found in the cytoplasm, 
full-length snoRNAs have never been shown to localize the same way. A notable analogy 
supporting guide RNA-dependent 2’-O-methylation on mRNA is ADAR family protein 
localization. From imaging experiments, snoRNPs seem to almost exclusively localize to the 
nucleolus and Cajal bodies, consistent with their putative functions. Nuclear ADAR1 and 
ADAR2 also show exclusive nucleolar localization; however, their dsRNA substrates are 
nucleoplasmic. Indeed recently, a group of ribosomal protein L13a (Rpl13a) intron encoded 
snoRNAs were discovered in the cytoplasm. While U32a, U33, U34 and U35a transcribed from 
the locus mainly reside inside typical locations in the nucleolus, stress conditions, specifically 
reactive oxygen species, triggered significant relocation into cytoplasm in a NADPH oxidase 
(Nox) regulated manner (Michel et al. 2011). These snoRNAs are guides for known rRNA 2’-O-
methylation sites, further expanding the multi-functionality of box C/D snoRNAs. This study 
showed that the snoRNAs are in the form of intact snoRNPs instead of potentially processed sno-
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miRNAs, suggesting any function implicated by the Nox regulated snoRNA relocation is 
independent of known mechanisms (Holley et al. 2015). Furthermore, the study also detected 
most of the known snoRNAs in the cytoplasm after ROS triggered stress, therefor identifying a 
broader spectrum of the phenomenon than with Nox alone.  
Confirmation of cytoplasmic snoRNAs opened the further possibility that snoRNPs could 
indeed modify mRNA internal sites, thus providing one potential explanation to major missing 
links between snoRNAs and human cancers, which have also been studied extensively recently. 
Currently, clinical studies have created correlations such as loss of: SNORD50 in prostate 
cancer, SNORD42 in non-small cell lung cancer, SNORD47/76 in glioblastoma, SNORD47/113 
hepatocellular carcinoma and SNORD44 head and neck squamous cell carcinoma and breast 
cancer, while SNORD50 is deleted in around 10% cases of most human cancers; even a fraction 
of box C/D snoRNAs are now characterized as biomarkers in leukemia (Patterson et al. 2017 and 
references therein, Ronchetti et al. 2013, Siprashvili et al. 2013). Could these snoRNAs direct 2’-
O-methylation on mRNAs with an effect in cancer? On the other hand, we cannot exclude the 
possibility that rRNA 2’-O-methylations are heavily involved in these diseases. Contrary to the 
notion that epigenetic regulation is considered part of transcriptional regulon, which in general 
has high level of variability between different organ tissues, epitranscriptomic modifications 
have not been widely explored in a similar way regarding ribosomal activity. SnoRNA 
expression levels have been known to exhibit distinct patterns under stress and disease 
conditions (reviewed in Stepanov et al. 2015). It is possible that rRNA 2’-OMe sites are 
dynamic, rather than static, features that can contribute to a layer of regulation during translation. 
Owing to potential complex interactions, it is possible that differential methylation of rRNAs 
might enable regulation of specific genes or subsets of genes. This notion is echoed in Xue & 
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Barna (2012), who proposed a model of dynamic ribosome biology. More interestingly, further 
investigation into ribosomes from within a single cell line revealed specialized ribosomal 
complexes, which have specific ribosomal protein compositions, and are active in translating a 
subset of messenger RNAs (Shi et al. 2017). It was further corroborated by the new evidence that 
rRNA sequences between different rRNA clusters are in fact different, rather than just repeats of 
the same sequences, suggesting potentially different binding affinities for various protein, RNA 
interaction partners (Kim et al. 2018).  
SnoRNA-guided 2’-O-methylation has been shown to be easily reconstituted in vitro without 
needing a long list of factors, suggesting that snoRNPs may be functional wherever they are 
localized within the cell. An ex-vivo study in Xenopus oocytes by injection of branch point 2’-O-
methylated pre-mRNAs showed strong preference of alternative splicing using cryptic branch 
points (Ge et al. 2010, Galardi et al. 2002). This report certainly demonstrated possible 
nucleoplasmic functions of RNA-guided 2’-O-methylation.  
The Prader-Willi critical region locus on chromosome 15 q11-q13 represents one of the most 
complex genomic regions that exhibits extensive splicing, anti-sense transcription and 
imprinting; this region is associated with the neurodevelopmental diseases Prader-Willi 
syndrome (PWS) and Angelman syndrome, but the exact molecular basis of the diseases has not 
been clearly understood (Figure 6, Chamberlain et al. 2010 and references therein). Within this 
locus are two clusters of orphan box C/D snoRNAs, the SNORD115 (H/MBII-52) and 
SNORD116 (H/MBII-85) clusters (Cavaillé et al. 2000, Bortolin-Cavaillé & Cavaillé 2012, 
reviewed in Cassidy et al. 2012). SNORD115 was identified as a brain-specific and imprinted 
snoRNA cluster (45 identical snoRNAs) and was predicted to target the serotonin receptor 5-
HT2RC gene through sequence complementarity. This predicted target coincides precisely with 
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known ADAR editing sites on the serotonin gene. Subsequent studies demonstrated that 1) The 
SNORD115 snoRNAs form canonical snoRNPs. 2) Expression of SNORD115 inhibits ADAR2 
editing of the serotonin receptor. 3) These snoRNAs influence exon inclusion decision on 5-
HT2RC (Vitali et al. 2005, Kishore & Stamm 2006). The SNORD116 cluster of 30 closely 
related snoRNAs is always deleted in PWS patients, but no targets have been identified (Bieth et 
al. 2015).  
Although no processed sno-miRNAs are found for SNORD116 cluster, two unusual RNA 
species are transcribed from the region: sno long non-coding RNAs (sno-lncRNAs), where a 
lncRNA is flanked by two snoRNA ends; and 5’-SnoRNA capped and 3’-PolyAdenylated (SPA) 
lncRNAs (SPA LncRNAs) (Yin et al. 2012, Wu et al. 2016). Unlike snoRNAs, sno-lncRNAs 
have predominantly nucleoplasmic localization and contain multiple binding sites for the 
splicing factor RBFOX2, a protein that is known to regulate alternative splicing. Both sno-
lncRNAs and SPA lncRNAs can form nuclear aggregations that trap at least RBFOX2 and two 
other proteins, and it has been proposed that the two lncRNAs function as sponges to sequester 
splicing factors and thus disrupt some normal splicing processes (Yin et al. 2012, Wu et al. 2016, 
reviewed in Li & Fox 2016). Although RBFOX2 overexpression in tissue culture affected the 
inclusion of a number of alternative exons as reported from sno-lncRNA study, the physiological 
relevance of the sequestration model remains to be validated. Interestingly, RBFOX2 has 
recently been reported to have a role in attenuating global Polycomb Complex II activity, 
suggesting that the sno-lncRNA and SPA-lncRNAs may affect more than splicing (Wei et al. 
2016). It is still not resolved whether, SNORD116 snoRNAs can behave similarly to SNORD115 
in terms of effects on splicing, or whether SNORD115 or SNORD116 induced 2’-O 
methylations on specific targets contribute to PWS.  
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Figure 6. Diagram for the genomic locus of the Prader-Willi Syndrome critical region. 
Anti-sense transcription is paternally silenced. Solid arrow represents the broad transcription activity that 
is common in most cell types. The dashed blue arrow represents the UBE3A antisense transcript that is 
only generated in neurons. UBE3A transcription from the sense strand is maternal allele specific in 
neurons, while bi-allelic transcription occurs in other cell types. Dashed brown lines indicate the 
minimum deletion region associated with PWS patients (Bieth et al. 2015). 
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So far, I have detailed numerous possible links between 2’-O-methylation and various 
observations. Although the report of viral mRNA internal 2’-O-methylation is promising (Dong 
et al. 2012), there remains a significant lack of direct evidence of the existence of 2’-O-
methylation on sites/genes of interest other than on rRNAs or snRNA. We can now clearly see 
the benefit of obtaining the methylation landscape, be it aiding in characterization of orphan 
snoRNAs, or investigating whether presence of a 2’-OMe correlates with splicing processes or 
studying methylation variability. It would allow us to study the modification more purposefully 
instead of relying on the chance of serendipitous discovery of new sites and/or potential 
functions.  
D. Insights into 2’-OMe in other organisms. 
Like human, the mouse also expresses a large number of snoRNAs. Consistent with the 
conservation of snoRNA machinery, not only snoRNP mechanisms are highly similar, introns of 
mouse snoRNA host genes are highly homologous to those of human counterparts despite much 
greater variation in the exons of the respective host genes (Ganot et al. 1999, Yoshihama et al. 
2013, Tanaka-Fujita 2007). Therefore, rodent samples have been used extensively in conjunction 
with human and yeast samples for many of the discoveries made in the field. Since mouse 
samples are more readily available compared to other higher eukaryotes while also being 
genetically and physiologically closer to human than most other model organisms, it could be an 
even more powerful tool now for snoRNA and 2’-O-methylation studies as we investigate 
further into the disease aspect of the snoRNA machinery. 
Some distantly related non-higher eukaryotic organisms exhibit particularly high levels of 2’-
O-methylation and the significance, besides less extensively studied, of this is also not yet clear. 
T. brucei is a protistan parasite causing deadly disease in sub-Saharan Africa – the African 
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sleeping sickness-. During its life cycle the parasite shuttles between its tsetse fly vector and its 
human host where it lives freely in the bloodstream (reviewed in Ponte-Sucre 2016). 
Trypanosomes possess 21 snoRNA clusters that are responsible for producing more than 90 
snoRNAs, of which 57 are box C/D. It was suggested by bioinformatic mapping and partial 
experimental validations that there are more than 130 2’-OMe rRNA sites in Trypanosome 
brucei (Uliel et al. 2004, Liang et al. 2005). Interestingly, differential methylation on the rRNA 
has been reported on two different life cycle stages of the organism. Consistent with the earlier 
mentioned dynamic ribosome model, the differential methylation detected was not a change in 
the overall level, but rather, changes in specific sets of sites (Barth et al. 2008).  Differential 
pseudouridylation has recently also been implicated in this transition (Chikne et al. 2016). The 
authors have inferred from thermophilic organisms, many of which have high numbers of 2’-O-
methylation sites, that the differential pattern could be a way help coping with increased 
temperature going from insect form to mammalian blood stream form. However, this assumption 
may rather predict an overall increase in methylation of the rRNA. Further investigation is 
required to understand the precise function of the 2’-OMe in T. brucei. Systematic profiling of 
the sites could be a starting point, followed by biophysical and other studies to determining their 
structural contributions, as well as whether they are involved in additional functions. Since T. 
brucei is a rather remote organism from higher eukaryotes in the evolutionary tree, studying it 
would also aid in further comprehension of the robustness of the regulatory roles of the 2’-OMe 
in human. 
E. Methods to study 2’-OMe. 
2’-OMe sites were traditionally detected using one of four strategies. The first strategy 
employs primer extension. The primer extension experiment utilizes polymerase pausing effects 
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when obstacles are encountered during extension. Such an effect is amplified when the 
experiment is carried out under limited dNTP concentrations, especially when encountering 
secondary structures and some bulky modifications. If RNA gel electrophoresis is performed on 
these primer extension products, bands corresponding to sites of polymerase stoppage can be 
seen. Thus, to detect/validate a suspected site, a downstream primer can be designed, and a 
primer extension experiment can be carried out (Figure 7A, Maden et al. 1995). A second 
method is based on the fact that ribose methylated bases are resistant to alkaline hydrolysis. If an 
RNA pool, such as total RNA, is hydrolyzed to shorter fragments, it is expected for any 
methylated RNA that hydrolysis will occur at every position except for the site of the methylated 
base. RT can then be performed with a primer specific to a transcript suspected to have 2’-OMe. 
The RT product is then visualized on a gel together with a sequencing ladder. For example, if 
only a base 150bp upstream of the primer is 2’-O-methylated, a fragment of 150bp would not 
exist after partial alkaline hydrolysis, and this would correlate with a gap at that base on a 
sequencing gel (Figure 7B, Kiss-László et al. 1996). A third method was developed based on the 
observation that RNaseH cleavage strictly requires perfect pairing between DNA and RNA 
molecules. For a suspected 2’-OMe site on human 18S rRNA for example, a short DNA oligo 
can be designed to hybridize to the region. After RNaseH digestion, visualization on a gel should 
show either presence or absence of the digestion products depending on whether the methylation 
indeed occurs at the region (Figure 7C, Yu et al. 1997). A final method is to purify a subset of 
RNA transcripts that are of interest and subject them through liquid chromatography and mass 
spectrometry after fragmentation into proper sizes (Qiu & McCloskey 1999).  
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Figure 7. Illustrations of conventional methods used for 2’-OMe detections and validation. 
(A) Low dNTP Primer Extension. Each RNA diagram represents different transcripts with different 2’-
OMe sites. Gene-specific primers are designed for targets of interests. Under low dNTP concentration, 2’-
OMe is enough to induce significant amount of pausing of the polymerase extension, resulting in a 
product pool with major species as the paused fragments.  
(B)  Alkaline Hydrolysis. Sequences in the diagram are multiple copies of one RNA transcript form of a 
hypothetical gene. Red-color highlighted bases are 2’-O-methylated. Because 2’-O-methylated bases are 
resistant to alkaline hydrolysis, the digestion cannot occur at 3’- of the 2’-O-methylated U base (the star 
labeled sequence). Thus, if the random digested product is reverse transcribed with a gene-specific 
primer, and visualized on a sequencing gel, there will be signal for every base that corresponds to 
hydrolyzed RNA fragments shown in top right panel. However, there will be a gap at 2’-O-methylated U 
position as a fragment from hydrolyzing the U cannot be generated. 
(C) RNaseH Assay. 2’-OMe disrupts perfect oligo-RNA annealing, thus preventing RNaseH digestion 
from happening. To test whether a several-base region contains a 2’-OMe, a radiolabeled 10bp oligo 
targeting the specific loci can be designed, and RNaseH assay carried out. The digestion product can be 
visualized on PAGE gel.  
 
 
 
 
 
 
 
46 
 
Methods Used in Detecting sites of 2’-O-methylation. 
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Although multiple methods were available for detecting a single modification, major 
drawbacks exist. In primer extension under low dNTP conditions, despite observations of 
polymerase pausing, 2’-OMe is a much weaker factor compared to RNA secondary structures 
and some other modifications that strongly affect base pairing (reviewed in Maden 2001). Such 
properties make this method highly prone to false positives for moderately long transcripts. It 
could be viable to pinpoint to a small stretch of RNA bases, but even then, one has to be aware of 
local secondary structures and other modifications. The RNaseH method is limited as a general 
confirmation tool due to its inability to map at single base resolution besides the same factors 
plaguing primer extension method also causing uncertainties of any results. The biophysical 
method using mass spectrometry remains highly accurate, however, it is also the most labor and 
cost intensive method and is unsuitable for the discovery of new sites. Furthermore, all methods 
described lack scalability. Although these methods were invaluable in identifying majority of 2’-
OMe sites on rRNAs, the less than 150 sites total detected were the result of decades long work 
and piecing together data from various labs. These methods at their current state are acceptable 
for validation purposes, but not suitable for explorative studies.  
To address the shortcomings of the conventional methods, two high-throughput strategies 
have been developed in recent years. RIM-seq and 2OMe-seq modify the low dNTP primer 
extension method and adapt it to Illumina sequencing workflow, thus enabling high -throughput 
profiling (Jorjani et al. 2016, Incarnato et al. 2016). Unlike primer extension experiments 
mentioned above, RIM-seq and 2OMe-seq use random primers, removing the restriction to the 
analysis of single transcripts; the products of primer extension are converted into Illumina 
sequencing libraries, sequenced, and analyzed (Figure 8A). However, the disadvantage of non-
specific pausing remains in this approach. In RIM-seq, more than 400 2’-OMe sites were 
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identified, at least 200 more than previously known, but it is unclear how many of the novel sites 
are true positives owing to the inherent high false positive rate of primer extension. 2OMe-seq 
attempts to partially alleviate the issue with the addition of a parallel fibrillarin knockdown 
experiment. The KD samples’ mapping should show decrease of signal for sites that are snoRNA 
guided. Thus, any sites detected in the non-KD samples that correspond to reduction in KD 
samples theoretically represent true sites. However, besides the necessity to double the sample 
amount, gene silencing experiments are known to introduce variables (Olejniczak et al. 2009). 
Ribometh-seq, on the other hand, combines alkaline hydrolysis with NGS. In this case, the 
alkaline hydrolyzed RNAs are directly converted into sequenceable cDNA libraries and 
sequenced (Marchand et al. 2016). The premise is that due to randomness of the hydrolysis, 
when enough RNA is supplied, there should be hydrolysis at every single position of all RNAs 
except for methylated bases. Thus, the presentation of the alignment would show mapped 3’-
ends on every single base position, while gaps would form on methylated ones (Figure 8B). 
Although the method has the advantage of being highly specific, its reliance on negative rather 
than positive signals can become an issue when applied to lower abundance RNAs such mRNAs. 
In addition, it is viable for rRNAs as there are less than 8kb distance to cover. However, for 
human mRNA with average length of about 3kb and around 100000 different types transcripts, a 
normal exome RNA-seq requires 30 million reads per sample, translating to 0.09 read per base, 
while Ribometh-seq would require 300 reads per-base, or 100 billion reads per sample for 
accurate 2’-OMe site calling. The cost for such sequencing effort is unattainable for most 
laboratories. 
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Figure 8. Available high-throughput methods for 2’-OMe detection. 
(A) RIM-Seq/2OMe-seq. Primer extension with low dNTP concentration is carried out with 
random primers. The RT cDNA product pool is then converted into a sequencing library. After 
sequencing and read alignment, read 5’-end enrichment is calculated for every base position.  
(B) Ribometh-seq. RNA is randomly hydrolyzed under alkaline condition. The digested 
fragments are converted into sequencing library and sequenced at very high depth. Because 2’-
O-methylated-base is resistant to hydrolysis, there does not exist any fragment that ends with that 
methylated base position. Thus, when read 3’-end enrichment is calculated for every base 
position, 2’-OMe site corresponds to the base position lacking read 3’-end mapping. 
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F. Thesis Objectives. 
As biotechnologies leaped forward in the past decade, the technological barriers preventing 
us from accurately and efficiently profile 2’-OMe sites are melting away. As discussed above, 
even with recent developments, our ability to accurately and efficiently profile 2’-OMe sites still 
remains unsatisfactory. To be able to test the 2’-OMe function centric model, and to answer the 
questions we proposed so far, we need a flexible and efficient way of profiling the sites 
transcriptome-wide. The main focus of this thesis, thus, will be the development of a highly 
specific and accurate high-throughput method detecting 2’-OMe sites. In Chapter II, I will 
summarize the strategy we used to selectively enrich 2’-OMe sites and its distinct features 
comparing to currently available methods. I will also present the developmental timeline and 
optimization steps taken. Finally, tests of these principles on human rRNA sites will be 
discussed. In Chapter III, I will discuss the current state of the method, as well as applications of 
the method. Due to the highly flexible nature of the method, I will be emphasizing on different 
directions we can take to improve and adapt the method in Chapter VI. 
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Chapter II 
Development of Ribose Oxidation Sequencing (Riboxi-Seq) For Profiling 2’-Ome Sites 
A. Abstract 
RNA modifications, or epitranscriptomic marks, are not only important for basic biological 
processes such as nominal ribosomal functions, but also have been implicated in cellular defects 
and diseases. Ribose methylation (2'-O-methylation, 2'-OMe) occurs at high frequencies in 
rRNAs and other small RNAs and is carried out using at least one shared mechanism across 
eukaryotes and archaea. It is one of the epitranscriptomic marks that have been identified to be 
involved in many cellular processes without clearly characterized functions. Evidence so far 
indicates 2’-OMe being mainly a structural feature, however, due to deficiencies in methodology 
studying the modification, there might be more to be learned even on rRNAs. Furthermore, the 
possibility of internal 2’-OMe sites on mRNA has been suggested (Dong et al. 2012, Holley et 
al. 2015), thus it is important to characterize the landscape of 2'-O-methylation.  Here we report 
the development of a highly sensitive and flexible method for ribose methylation detection using 
next-generation sequencing. A key distinction of this method is to use sodium periodate to enrich 
2’-OMe sites, allowing only RNAs harboring 2'-OMe groups at their 3'-ends to be sequenced. 
Although currently requiring microgram amounts of starting material, this method is robust for 
the analysis of rRNAs even at low sequencing depth. An important feature of the method is that 
it can be expanded to work on a transcriptome-wide scale with minimal revision. 
B. Background 
A great majority of 2’-O-methylations are directed by Box C/D snoRNAs, noncoding RNAs 
that guide the modification of target sites via complementary RNA sequences. In humans, 
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snoRNAs are assembled into snoRNP particles, containing the conserved core proteins NOP56, 
NOP58, 15.5K, and fibrillarin (the catalytic component) (Tycowski et al. 1996; Filipowicz & 
Pogači 2002; Watkins & Bohnsack 2012). 2’-O-methylation has been extensively studied for a 
number of years with the goal of establishing functional and mechanistic links with specific 
biological pathways. Although, early studies demonstrated that 2’-O-methylations on rRNAs are 
prevalent during ribosome biogenesis, depleting several snoRNA guides alone or generating 
fibrillarin heterozygous mutations does not produce noticeable defects (Newton et al. 2003). 
However, homozygous mutations of fibrillarin have been shown to be embryonically lethal in 
mouse, thus suggesting that this gene is essential for organism development (Tollervey et al. 
1993, Newton et al. 2003). Such evidence strongly suggests that the modification could have 
important roles. 2’-O-methylation has also been shown to be present on tRNAs and has been 
implicated to be crucial in translational circuitries (Satoh et al. 2000; Guy et al. 2015). A 
substantial portion of known methylated sites in rRNA lie in close proximity to ribosome 
functional sites such as regions around the peptidyl transferase center, suggesting the potential 
involvement of such modifications in rRNA folding, stability, and translation (Decatur & 
Fournier 2002). Ribose methylated bases are also found at mRNA caps and are involved in host 
pathogen responses (Daffis et al. 2010; Rimbach et al. 2015). Additionally, 2’-OMe adenosines 
have been found within, rather than at the cap, of flavivirus RNA transcripts. Homology between 
2’-O-methyltransferases of Flavivirus, Dengue-1 and West Nile also suggest a more common 
phenomenon (Dong et al. 2012). Furthermore, recent evidence indicates that in addition to being 
associated with the 5’ cap, mRNAs might potentially possess internal 2’-O-methylated sites (Lee 
et al. 2016, Holley et al. 2015). Thus, currently available data hint that there is an increasing 
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possibility that 2’-OMe possesses much more expansive regulatory roles than in ribosome 
biogenesis. 
The list of known 2’-O-methylation sites is frequently updated, as experimental techniques 
evolve and mature. However, until recently, a major hurdle in obtaining a more complete profile 
of the 2’-O-methylation landscapes has been the lack of an efficient and reliable modification-
specific and high-throughput detection method. Methylation sites have traditionally been mapped 
using targeted approaches including primer extension under limiting dNTP concentrations, 
where reverse transcriptase stalls when encountering a methylation site, or resistance to RNaseH 
digestion when synthesized DNA oligos are introduced (Yu et al. 1997; Maden 2001). Primer 
extension experiments are particularly prone to false positives for detecting 2’-O-methyl sites 
due to nonspecific polymerase pausing or secondary structure-induced pausing, while RNaseH 
assay lacks base resolution. Most importantly, both methods require laborious mass spectrometry 
to validate a detected site (Qiu & McCloskey 1999). Also, neither is suitable for de novo site 
detection and high-throughput screening, because the base position needs to be known in 
advance for primer or hybridization oligo design. This makes primer extension and RNaseH 
assay most useful as confirmation tools. Recently, primer extension, as described in RIM-seq and 
2OMe-seq, has been adapted for high-throughput detection of ribose methylation sites by 
combining random priming with next-generation sequencing (Incarnato et al. 2016; Jorjani et al. 
2016). This study identified over 400 sites, almost 300 more than what have been curated in 
human rRNAs (Lestrade & Weber 2006). It is unclear, however, how many of the novel sites are 
true positives, owing to an inherent high false-positive rate of primer extension. Although 
potential matches to BoxC/D snoRNAs were bioinformatically identified for some of the novel 
sites found in the study, methylation could not be confirmed, because there are known snoRNAs 
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that interact with targets without guiding the deposition of methyl on ribose (Cavaillé & 
Bachellerie 1998; Lafontaine 2015). As a consequence, these sites might not accurately represent 
the methylation pattern until they are further validated. 
Alkaline hydrolysis is another conventional method used to identify 2’-OMe. Due to the 
resistance to hydrolysis of a base modified by 2’-OMe, fragmented RNAs can be reverse 
transcribed and gaps correlating to the sites are visualized on gel (Kiss-László et al. 1996). 
Although alkaline hydrolysis is very specific to 2’-OMe, the site needs to be known in advance. 
Ribometh-seq was developed recently and utilizes the property of alkaline hydrolysis of ribose 
methylated bases. Thus, by randomly hydrolyzing RNA and performing next-generation 
sequencing at very high depth, there should be uniform coverage of 3’-end positions across 
regions of interest except at positions of 2’-O-methylation. This method overall has much better 
specificity and accuracy, as it has successfully detected about the same number of sites in rRNAs 
as have been annotated. Several novel sites were also validated by mass spectrometry (Krogh et 
al. 2016). However, the method relies heavily on negative rather than positive signals. In 
addition, the requirement for high read depth and coverage makes such studies costly, and the 
method can also suffer from high background noise due to resistance to alkaline hydrolysis of 
highly structured regions. In order to address these issues, we have developed a 2’-O-methyl 
ribose-specific, high-throughput method, which relies on positive rather than negative signals, to 
detect 2’-O-methylation sites. 
C. Method development, Methods and Materials  
1. Methodology development 
Development of an accurate method for 2’-OMe detection is best achieved by utilizing a 
modification specific strategy. Unlike other modifications such as m6A and m1A, there is no 
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antibody available for 2’-OMe, nor does there exist any 2’-OMe specific chemical modifier that 
enables purification. As a consequence, other strategies for enriching 2’-OMe had to be 
considered.  
Random digestion is a common strategy for Illumina based regular RNA sequencing, as it 
reduces RNA transcript to a more uniform length appropriate for the sequencer. The result is that 
there will be RNA fragments generated such that each fragment represents 5’- and 3’- ends of a 
portion of the original RNA transcript. When mapping these fragments back to the genomic 
sequence, a pattern representing distinct 5’- and 3’- ends, each with similar frequency, can be 
obtained. Such a property is useful because when combined with more stringent digestion, which 
generates shorter fragments, there will be a higher probability that a random base will be present 
at 5’- or 3’- end of a fragment (Figure 9A). Ribometh-seq for example exploits this particular 
chemistry together with ribonucleic acids’ resistance to hydrolysis if 2’-O-methylated, thus 
producing a sequencing pattern where appearances of negative signal are dictated by probability.  
However, to achieve a positive signal, resistance to hydrolysis is not enough, because 2’-O-
methylated ends can never exist in the digestion product due to their resistance. The closest that 
random degradation can achieve is 1 base upstream of the 3’-end of a fragment (Figure 9A). To 
ensure that 2’-OMe sites are represented at the ends of the fragments at all, it is necessary to 
remove at least 1 nucleotide either from the 3’-end. Removing more than 1 base, which will be 
discussed later, can greatly increase sensitivity, although it can make the procedure rather 
laborious. Through literature searches, we found a stepwise strategy to degrade RNA base by 
base that has been available since the 20th century. In this strategy Alefelder et al. (1998) first 
oxidized RNA 3’-ends using sodium periodate (NaIO4), which have 2’- and 3’- OH groups (cis-
diols), into 2’-, 3’- dialdehydes. Such dialdehyde structures are prone to β-elimination, which 
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removes the oxidized RNA terminal oligonucleotides. The resulting products will contain 
terminal 2’-O-methylated bases with 3’-phosphates and nonmethylated bases with a mixture of 
cyclic-phosphates, 3’-phosphates, and 2’-phosphates (Figure 9B).  
By extensively hydrolyzing RNAs to sizes smaller than those obtained in the Ribometh-seq 
protocol, we speculated that we should be able to generate a pool of RNA fragments that has 
sufficient 2’-O-methylated ends to provide grounds for the rest of the procedures. However, 
instead of -OH groups at 3’-terminal bases’ 2’-ribose positions required by oxidation, alkaline 
hydrolysis produces 2’- phosphate groups. To simplify our pilot experiments, we found a 
commercially available enzyme called Benzonase nuclease, which is both an endonuclease and 
an exonuclease, and which generates cis-diols when used for digestion (Figure 9C, Sigma-
Aldrich). Benzonase nuclease, unlike most other RNAses, does not have a sequence bias. 
Therefore, we expected digestions with Benzonase to behave similarly to alkaline hydrolysis.  
 With 2’-OMe exposed, we next sought to enrich these ends. Conveniently, 2’-O-methylated 
bases have been shown to be resistant to NaIO4 oxidation we used for beta elimination. This 
could serve as a perfect strategy to convert all non-methylated ends into dialdehydes while 
keeping 3’-terminal bases with 2’-OMe intact. Indeed, an earlier publication on a quick ligation 
protocol used this property to convert un-ligated products, which have cis-diols at their 3’-
terminal ends, into dialdehydes to enrich ligated products that have unreactive 3’-ends (Kirino & 
Mourelatos 2007, Kurata et al. 2003). The oxidized RNA fragments should then be ready for 
sequencing library preparation, which requires ligation of a linker to the fragments’ 3’-ends in 
order for subsequent conversion into cDNA using RT. Because fragments with dialdehydes at 
their 3’-termini are incompatible with ligation, only the ones that have terminal 2’-OMe groups 
are converted into the cDNA library. PCR amplification can then be performed to generate the 
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final library that is labeled with sequences recognized by the Illumina sequencer, which was 
introduced with the PCR primers (Figure 9D).  
18S rRNA (SSU) and 28S rRNA (LSU) add up to about 7kb in length, where there are 
around roughly 150 known 2’-OMe sites, averaging around 1 2’-OMe per 50 bases. Depending 
on the efficiency of 2’-OMe site exposure after fragmentation and beta elimination, we expect 
the final terminal 2’-OMe numbers to be relatively low. As a consequence, one caveat of the 
proposed library preparation strategy is that after oxidation, the number of fragments available 
for ligation and conversion into sequenceable reads might become too small without having to 
drastically increasing starting materials. Two potential issues can occur: first, extremely small 
quantities in general are hard to quantify; second, PCR preferential amplification can greatly 
alter original ratios between different fragments. The first problem can be addressed by 
increasing PCR cycles, however, this worsens the PCR bias outcome. To remedy these issues, 
we include a random sequence portion into the RT primer. In general, digestion of RNA does not 
generate fragments with exactly the same 5’ and 3’ ends. Thus, if two sequenced reads have 
exactly the same RNA portion and same random sequence, these are most likely generated from 
PCR amplification, and are thus duplicates. The inclusion of the random sequences allows us to 
remove these PCR duplicates during data processing, thus reducing the overall bias of the 
procedure while keeping the starting material amount relatively low (Figure 10A).  
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Figure 9. Chemical principle of the RibOxi-seq. 
(C) Property of random digestion. In theory, every base position of an RNA transcript can be 
cleaved, generating fragments with variable 3’-ends. These 3’-ends cannot contain 2’-O-
methylated bases as explained earlier in the thesis. The bottom left panel represents the type 
digestion products where a 2’-OMe is 1 nucleotide upstream of RNA 3’-end, which is the species 
concerned in the method. The right panel shows other possible background RNA species. 
(D) β-elimination. Elimination of one 3’-terminal nucleotide for exposure of 2’-OMe. 
(E) Random Digestion strategies. RNA transcripts hydrolyzed under alkaline condition 
generate fragments with 3’-phosphates, which require extra steps before elimination can be 
performed. On the contrary, Benzonase digested fragments possess the cis-diol structure that is 
directly compatible with elimination. 
(F) Enrichment of terminally methylated RNA fragments. RNA mixture obtained from β-
elimination is undergone NaIO4 oxidation a second time. Because fragments with terminal 2’-
OMe are protected from oxidation, only non-methylated fragments are converted into di-
aldehyde ends. Subsequently, only fragments protected by 2’-OMe can be converted into 
sequencing library and sequenced. 
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The sequencing reads obtained from the Illumina sequencer first need to be analyzed to 
remove PCR duplicates discussed above followed by trimming to remove the random sequences, 
as well as the linker sequences introduced during ligation. The processed reads can then be 
aligned to a reference genome. The 3’-terminal bases of the aligned reads correspond to the 
original RNA 2’-O-methylated 3’-ends. We speculated that by counting these ends, we would be 
able to see a pattern that is largely consistent with the distribution of known 2’-OMe sites (Figure 
10B). 
In order to statistically evaluate the results, a control group for each sample is needed. To 
properly control for the method, we proposed to have additional samples undergo exactly the 
same procedures except for the oxidation step. Such preparations of the control samples should 
not show enrichment of 2’-O-methylated ends, thus generating a relatively uniform alignment 
pattern across the reference genome. On the contrary, they should show a lack of ends mapping 
to 2’-OMe sites reminiscent to the principles of Ribometh-seq (Figure 8B, Figure 10B). 
Subsequently, end-counting data can be analyzed using DESeq2, a bioinformatic tool for 
differential expression analysis. DESeq2 compares control data, where ends are distributed 
evenly, with oxidized data, where ends align at specific positions. The program uses a negative 
binomial statistical model to evaluate the differential between the two and assigns significance 
values, as well as computing log2 fold changes for every position (Figure 10B, Love et al. 2014). 
We would then be able to examine data and determine the optimum cutoff for 2’-OMe site-
calling. 
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Figure 10. Continuation of RibOxi-seq  
(A) Library preparation and PCR duplicates removal strategy. Random hexamer sequence 
is introduced as part of the RT primer. After PCR amplification, any identical ends together with 
identical random sequence is considered PCR duplicate and can be removed later 
bioinformatically. 
(B) RibOxi-seq data processing, analysis and visualization. Enrichment of read 3’-ends at 
sites of 2’-O-methylation (bottom left panel). When counting just 3’-ends, the data can be 
visualized in top right panel. 
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To summarize the key principles of the proposed method: first, fragmented RNAs containing 
3’-ends that are either unmethylated or 2’-O-methylated are obtained using random digestion 
followed by β-elimination; then, an oxidation step renders the nonmethylated ends incapable of 
ligation to linkers used for high-throughput library construction; after sequencing, the reads are 
aligned to a reference genome and only positions of the 3’-ends of aligned fragments are counted 
and displayed for each base position; the count data for oxidized and nonoxidized samples are 
then normalized, compared, and analyzed using DESeq2 for single-base resolution methylation 
site determination. The major difference between our method and currently available methods is 
its specificity and its reliance on positive rather than negative signals. The cis-diols of non-2’-O-
methylated ribose are converted into dialdehydes using NaIO4, thus preventing them from being 
ligated to linkers for sequencing library construction. The advantage of this step over alkaline 
hydrolysis is that Benzonase leaves terminal ends with 2’-OH instead of phosphate group, thus 
eliminating an extra dephosphorylation step.  
Before starting the pilot experiments, it would be to our advantage to determine whether 
Benzonase nuclease is able to cleave at 2’-O-methylated bases, removing the requirement of 
eliminating a 3’-terminal base. To test this, we designed an oligo that is fully methylated. A 
digestion of the oligo shows that Benzonase does not cut at 2’-O-methylated bases (Figure 11A). 
Therefore, β-elimination is still required. 
We started our experiment by optimizing Benzonase nuclease digestion through time course 
and temperature gradients with PA1 cell total RNA. Benzonase rapidly degrades RNA within 
minutes at room temperature, leaving little room for optimization. Thus, all digestions were 
carried out on ice. The aim was to obtain the smallest fragments without exceeding the lower 
detection limit of the Agilent TapeStation (25bp), which is an imaging system that allows very 
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fast visualization and quantification of nucleic acids. Several digestion time courses helped to 
determine our target sizes to be an average of 70bp (Figure 11B). 
Next, we proceeded with β-elimination. As mentioned earlier, the reaction leaves a mixture 
of terminal cyclic-phosphates, 3’-phosphates, and 2’-phosphates on non-methylated fragments. 
To enrich methylated ends, oxidation is required to inactivate non-methylated ends, which 
require terminal cis-diols. Thus, a phosphatase treatment was necessary. Most available 
phosphatases, such as calf intestine alkaline phosphatase, are only active in removing 3’-
phosphates. If used, nonmethylated bases with 2’-phosphates would survive the oxidation step 
and generate false-positive signals in sequencing. To prevent this phenomenon, T4 
polynucleotide kinase (T4 PNK) was used. Although less efficient than other widely used 
phosphatases, the advantage is that this enzyme nevertheless is capable of removing all three 
types of phosphates under acidic conditions in the absence of ATP (Cameron & Uhlenbeck 1977, 
Das and Shuman 2013, Kirino & Mourelatos 2007). It has been shown that T4 PNK's 
phosphatase activity is sufficient to remove the majority of the phosphates in <40 min at 37°C 
(Honda et al. 2016). Since RNA fragments with phosphates can generate bias in subsequent 
steps, we have increased enzyme concentration and extended incubation time to 4 h. With proper 
end treatment, the mixtures generated after β-elimination and T4 PNK treatment contain 
fragments with ends of either cis-diol or 2’-OMe,3’-OH.  
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Figure 11. Protocol optimization  
(A) Confirming Benzonase inability to cleave at site of 2’-OMe. 50bp RNA oligo is designed 
to have locked DNA bases except for the 4 2’-O-methylated RNA bases in the middle. Digestion 
using Benzonase was visualized on Agarose gel (top) and tapestation (bottom). 
(B) Digestion time course. Bottom panel represents the size distribution corresponding to the 
last lane in top panel with 75min digestion time. 
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After another NaIO4 oxidation treatment, we needed to ligate a linker to provide sequence 
complementarity for subsequent reverse transcription primers. Different variants of the T4 RNA 
ligases are known to have different reactivities toward different substrates and some of them 
generate bias toward certain base identities. Our goal was to minimize sequence bias during the 
ligation step and also maximize efficiency. It has been shown that both T4 RNA ligase I and II 
are biased against 2’-O-methylated bases, while ligase I has further bias against 2’-OMe-U 
(REF). Under optimized condition however, T4 RNA ligase II is able to ligate pre-adenylated 
linkers to RNA with 2’-OMe ends at acceptable efficiency, while displaying almost no base 
identity bias (Munafó & Robb 2010, Zhuang et al. 2012, Raabe et al. 2014). We thus followed 
the available optimized protocol to ligate 3’- linker. A 5’-linker is then ligated prior to reverse 
transcription for PCR primer annealing in a later step. We then tested both 5’ and 3’ ligation 
using primers complementary to the ligated linkers and showed that ligation was successful. At 
this step, we wanted to have at least partial confirmation that the basic chemistry works before 
finishing the library preparation and proceeding to sequencing. We designed 3 rRNA forward 
primers at distinct locations and PCR amplified the cDNAs of both control and oxidized samples 
with RT primer as reverse primer. We observed a continuous smear in controls while oxidized 
samples displayed distinct bands, consistent with the notion that fragments should have a 
uniform distribution in control but ends accumulating only on methylated positions in oxidized 
sample (Figure 12). The validation encouraged us to proceed with final steps of library 
preparation and subsequent sequencing.  
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Figure 12. Library validation using PCR  
Refer to main text for details 
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The initial sequencing was done with 2 biological replicates for each control and oxidation 
experiments on Illumina MiSeq sequencer, which generated a minimum number of reads. 
Although low read counts may negatively affect accuracy, this was enough for a proof-of-
principle experiment. Sequencing results were analyzed with a custom bioinformatic pipeline, 
which is presented at the end of this Chapter. Comparison of our data with available 2’-OMe 
databases was performed, to ensure our goal was achieved, prior to increasing to 3-replicates per 
sample and switching to the Illumina NextSeq platform, which generated 5 times more data. 
2. Cell culture and RNA extraction 
RNAs used in the initial experiments described in this chapter were extracted from the 
human ovarian cancer PA1 cell line and HEK 293T cell line. Both cell lines were cultured using 
regular DMEM 1X media supplement with 10% FBS as well as 1x Penicillin-Streptomycin in 
15cm Petri dishes. Cells were lysed on the dish when reaching confluency with lysis buffer from 
PureLink® RNA Mini Kit followed by RNA extraction and on-column DNase treatment 
according to the manufacturer’s protocol. Total RNAs used in the WT vs. KO experiments were 
extracted from either wild type, U32 snoRNA KO or U32+U51 snoRNA double KO 293T 
provided by the Holley lab at Duke University. 
3. PCR validation of cDNA 
Forward primers for 3 distinct 18S rRNA locations were used in conjunction with RT primer 
to amplify 1 µL of cDNA obtained from reverse transcription during the RibOxi-seq protocol. 
Additional 11.5 µL H2O and 12.5 µL NEB OneTaq master mix was used for the reaction per 
manufacturer’s protocol. Extension time was set to 10 seconds due to the short nature of the 
templates. The PCR product was run on a 1.5% agarose gel for 2 hrs. 
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4. Anti-sense oligo (ASO) knock down of U63 snoRNA 
 ASOs targeting 2 regions of the snoRNA were designed and ordered from IDT. PA1 cells 
were cultured as described above. When cultures became confluent, KD was performed using 
Lipofectamine 2000 following the manufacturer’s protocol. Sample setup was: 2 biological 
replicates for both ASO1, ASO2 and scrambled KD. RNA extractions were performed 48hr post 
transfection using PureLink RNA mini kit. Knock down efficiency was evaluated by qPCR using 
miScript II RT Kit and miScript miRNA PCR array kit (Figure 13). RNA was then used in 
RibOxi-seq once KD had been confirmed. 
5. Radioactive primer extension 
For novel site validation, primers were 32P labeled. One microgram of total RNA, 1 µL (10 
µM) labeled RT primer, 1 µL 100 µM or 1 µL 10 mM (control) concentrations of dNTPs, 7 µL 
of water were denatured at 65°C for 5 min, then chilled on ice. An RT Master mix (10 µL per 
reaction) containing 2 µL 10× RT Buffer, 1 µL (40 U) RNase Out, 1 µL AMV RT (NEB), and 6 
µL water was prepared, and added to the RNA/primer mix. Incubation was at 42°C for 45 min. 
Reactions were ethanol precipitated and resuspended in loading buffer for TBE-PAGE 
electrophoresis. This experiment was performed for three selected sites from RibOxi-seq: 
positive control at 28S C1880 (lanes 1,2), known but not detected 18S U1668 (lanes 4,5) and 
newly detected and not previously reported 28S A3717 (lanes 6,7). The first lane of each set is a 
negative control where primer extension was performed with a higher dNTP concentration. The 
second lane of each set was performed at low dNTP concentration to promote polymerase 
pausing at sites of 2’-OMe. 
 
74 
 
Figure 13. QPCR verification of U63 KD efficiency.  
U63_1 and U63_2 represent two U63 specific ASO used for KD. Non-specific KD was carried 
out using scrambled ASO.  
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D. Results 
1. RibOxi-seq accurately identifies annotated 2’-O-methylation sites within 18S and 28S 
rRNAs.  
RibOxi-seq was used to analyze total RNA from the human ovary teratoma-derived PA1 
cell line. Site detection was filtered by a combination of log2 fold change and adjusted P-value 
from the DESeq2 output. All site-annotations and numbering correspond to the hg19 reference 
genome. The lists of known sites we used were curated as previously described (Krogh et al. 
2016). By applying a cutoff value of log2 fold change of >7 and adjusted P-value of <0.0001, 39 
out of 40 known 18S sites and 60 out of 66 known 28S sites were detected with high confidence 
(Table 3, Table 4). The filters were set to correspond to the known sites that have the lowest log2 
fold changes and the highest P-values to allow maximum sensitivity (Figure 14). The number of 
high confidence sites consisted of 93.3% known sites, which include sites newly found and MS 
validated by Krogh et al. (2016) using Ribometh-seq. Using such cutoffs, only three novel sites 
(18S: U354, 28S A1322, and A3717) were found. However, when filters were slightly relaxed to 
log2 fold change of >6 and adjusted P-value remained unchanged, eight total potential novel 
sites were identified (Table 4). Among these candidates, A3717, which displays both a very high 
log2 fold change (∼10) and a low adjusted P-value (∼1.5 × 10−13), in 28S was validated using a 
primer extension under restricted dNTP concentration (Figure 15). Blasting A3717 in 
combination with surrounding bases within the snoRNA database resulted in two potential 
snoRNA guide hits, HBII-180B and U37, whose guides are complementary to this region and 
fulfill criteria for methylation at the fourth or fifth base of the rRNA complementary sequence. 
Although these two snoRNAs were previously noted to also methylate other positions within 
28S, snoRNA-guided methylations of multiple targets is known to occur (van Nues et al. 2011). 
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As only a few novel sites of methylation in rRNAs in human have been characterized within 
recent years, this result argues that the RibOxi-seq method not only identifies known 2’-OMe 
sites, but also allows the discovery of new ones.  
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Table 3. List of 2’-O methylation sites found in 18S and 28S rRNA from PA1 cells 
18S: 
chrUn_gl00022
0 
coordinate 
Base 
position 
Base snoRNAs Novel? Detected? log2FC adjusted p value 
109104 27 A U27 no  yes 17.92943 3.43E-36 
109176 99 A U57 no  yes 12.66704 1.68E-191 
109193 116 U U42A/B no  yes 12.43167 2.18E-69 
109198 121 U mgh18S-121/Z17B no  yes 14.57216 3.9E-249 
109236 159 A U45A/C no  yes 9.515039 6.76E-08 
109243 166 A U44 no  yes 12.78353 3.81E-12 
109249 172 U U45A/B no  yes 10.19354 1.51E-11 
109251 174 C SNORD45C  no  yes 11.79013 5.83E-73 
109505 428 U HBII-202 no  yes 9.514961 5.07E-69 
109513 436 G HBII-429 no  yes 7.66968 1.64E-45 
109539 462 C U14A/B no  yes 12.0917 9.85E-34 
109545 468 A SNORD83A/68 no  yes 12.55015 4.02E-50 
109561 484 A U16 no  yes 11.59956 1.64E-25 
109586 509 G HBII-95/B no  yes 7.985352 3.07E-10 
109589 512 A HBII-234 no  yes 12.83362 1.98E-74 
109594 517 C U56 no  yes 14.91788 2.85E-71 
109653 576 A HBII-336 no  yes 13.86214 9.17E-81 
109667 590 A U62A/B no  yes 10.33406 6.34E-10 
109679 601 G HBII-251/U103/B no  yes 12.56987 1.75E-22 
109704 627 U HBII-135 no  yes 9.429529 3.18E-12 
109721 644 G U54 no  yes 12.67708 9.15E-18 
109745 668 A U36A/B no  yes 11.75379 3.81E-16 
109760 683 G HBII-108/B no  yes 14.08851 2.06E-51 
109874 797 C ZL107/GGgCD20 no  yes 9.685468 2.90E-63 
109876 799 U U105/B no  yes 10.46362 5.47E-06 
109944 867 G HBII-419 no  yes 10.21481 2.95E-46 
110108 1031 A U59A/B no  yes 7.713374 2.73E-05 
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110349 1272 C HBII-142 no  yes 7.509314 7.58E-14 
110365 1288 U HBII-55 no  yes 12.14759 4.76E-68 
110403 1326 U U33 no  yes 8.592145 4.66E-07 
110405 1328 G U32A no  yes 8.730437 1.33E-06 
110460 1383 A SNORD30 no  yes 11.30044 1.58E-19 
110468 1391 C U28 no  yes 14.38748 2.14E-42 
110519 1442 U U61 no  yes 8.874819 3.31E-11 
110524 1447 G SNORD127 no  yes 11.02978 3.65E-119 
110567 1490 G U25 no  yes 9.173948 4.75E-09 
110745 1668 U Unknown no  no   
110755 1678 A U82 no  yes 12.47255 5.01E-51 
110780 1703 C U43 no  yes 11.16467 9.52E-40 
110881 1804 U U20 no  yes 13.96577 2.07E-79 
 
  
28S: 
chrUn_gl000
220 
 coordinate 
Base 
position 
Base snoRNAs Novel? Detected? log2FC adjusted p 
value 
113745 397 A U26 no yes 8.330468 5.02E-34 
113747 399 A U81 no yes 12.62798 5.39E-41 
114663 1315 G U21 no yes 9.655468 2.27E-52 
114670 1322 A  yes yes 7.772448014 1.46E-46 
114673 1325 A U18A/B/C no yes 11.56306 1.42E-40 
114687 1339 C U104 no yes 8.451424 8.58E-20 
114869 1521 G snR39B no no   
114871 1523 A U32A/B/U51 no yes 10.86955 1.06E-20 
114881 1533 A U77/U80 no yes 8.162373 1.46E-07 
114972 1624 G U80 no yes 11.99951 1.80E-38 
115107 1759 G  no yes 9.31923 1.37E-25 
115218 1870 A U38A/B no yes 10.96471 4.15E-14 
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115228 1880 C  no yes 10.55289 7.79E-34 
115639 2291 C U48 no no   
115698 2350 C U24 no yes 9.587046 8.89E-23 
115710 2362 A U76 no no   
115712 2364 C U24 no yes 11.3781 2.84E-77 
115748 2400 A HBII-202 no yes 9.007025 2.18E-26 
115762 2414 U ZL5/6/SNORD143/144 no yes 11.36035 2.97E-23 
115769 2421 C mgh28S-2409 no yes 13.18647 6.38E-171 
115771 2423 G mgh28S-2411 no yes 10.01012 3.45E-17 
116134 2786 A HBII-420 no yes 7.649203 6.31E-05 
116151 2803 C U55 no yes 8.838489 1.27E-79 
116162 2814 A U95 no yes 12.29032 7.88E-34 
116171 2823 C U95 no yes 10.82754 1.51E-60 
116184 2836 U U34 no yes 11.68902 7.29E-20 
116208 2860 C U50 no yes 11.05747 9.81E-28 
116223 2875 G U50 no yes 9.26956 1.08E-19 
116974 3626 G  no yes 11.41354 1.91E-47 
117049 3700 C HBII-180A/B/C no yes 11.8941 1.28E-35 
117065 3717 A HBII-180B yes yes 10.24109708 1.54E-13 
117067 3719 A U37 no no   
117071 3723 A U36C no yes 10.50822 2.07E-14 
117091 3743 G HBII-276 no yes 6.466373 5.50E-09 
117107 3759 A U46 no yes 8.50116 4.32E-10 
117132 3784 A U15A/B no yes 10.15055 8.93E-11 
117139 3791 G SNORD15A no yes 10.0732 1.37E-29 
117155 3807 C mgU6-77 no yes 6.963681 3.84E-23 
117165 3817 U ACA48/HBI-43 no yes 12.21898 1.79E-45 
117172 3824 A U30 no yes 11.44786 5.37E-33 
117177 3829 A U79 no yes 13.18303 1.53E-54 
117188 3840 C U74 no yes 13.59508 9.18E-208 
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117214 3866 A HBII-316 no yes 10.11454 4.60E-95 
117216 3868 C U53 no yes 11.55245 3.30E-129 
117234 3886 C U47 no yes 9.185954 5.57E-10 
117246 3898 G HBII-99/B no yes 10.27247 1.36E-30 
117272 3924 U U52 no yes 9.274559 1.51E-11 
117291 3943 G HBII-82/B no yes 12.25001 1.73E-127 
117391 4043 G U102 no no   
117401 4053 C U75 no yes 8.835343 1.99E-05 
117543 4195 G U31 no yes 12.39906 5.00E-31 
117574 4226 U U58C no yes 9.428109 4.73E-32 
117575 4227 G U58A/B/C no yes 10.08335 1.34E-49 
117653 4305 U U41 no yes 11.59332 8.11E-19 
117717 4369 G U60 no yes 9.848911 1.48E-13 
117739 4391 G snR38A/B/C no yes 10.2434 6.89E-19 
117803 4455 C U49A/B no yes 11.95609 2.11E-135 
117841 4493 G HBII-210 no yes 10.71001 3.04E-57 
117845 4497 U SNORD62A/B no no   
117846 4498 G SNORD62A/B no yes 10.83552 5.26E-85 
117870 4522 A U29 no yes 9.798517 1.09E-12 
117883 4535 C U35A/B no yes 12.49586 9.45E-251 
117918 4570 A U63 no yes 8.764135 7.07E-11 
117937 4589 A SNORD119 no yes 11.60263 8.32E-131 
117965 4617 G HBII-296A/B no yes 8.407214 1.45E-52 
117967 4619 U HBII-240 no yes 10.46333 1.10E-90 
117970 4622 G U78 no yes 11.90306 4.03E-95 
117984 4636 G SNORD121A/B no yes 9.767133 1.42E-39 
Sites determined by filtering DESeq2 analysis output (libraries sequenced on Illumina nextseq) 
using log2FC (>6) and adjusted p value (0.0001).  Positions highlighted in blue are sites that are 
annotated but not detected using our method. 
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Table 4. List of potential novel sites found in PA1 cells using RibOxi-seq.  
chrUn 
position 
Base 
position  base snoRNA Novel? Detected? 
Log2 fold 
change 
Adjusted p 
value 
18S:  
109431 354 U  yes yes 8.162207 2.42E-07 
109981 904 A  yes yes 6.712134 1.57E-13 
110632 1555 U  yes yes 6.122584 4.72E-18 
28S:  
114670 1322 A  yes yes 7.772448 1.46E-46 
114671 1323 A  yes yes 6.73175 3.05E-10 
114672 1324 A  yes yes 6.638669 1.08E-09 
117065 3717 A HBII-180B/U37? yes yes 10.2411 1.54E-13 
117233 3885 G   yes yes 6.083689 2.33E-21 
18S: U354, 28S:  A1322 and A3717 were detected even with stringent filter (log2 fold change 
> 7 and adjusted p value < 0.0001), while the rest were found with analysis threshold set to 
log2 fold change > 6 and adjusted p value < 0.0001.  
    
 
 
 
 
 
 
 
 
 
 
2. RibOxi-seq results confirm methylation heterogeneity within the same cell line.  
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Among already annotated 2’-O-methylation sites, U4497 and G4498 in 28S are 
positioned immediately adjacent to each other. One limitation of the RibOxi-seq method is that if 
two sites back to back are both methylated, the site closer to the 5’-end cannot be detected if the 
other site is fully methylated. This is because Benzonase (as well as other ribonucleases and 
alkali) cannot cleave at the 3’-site of 2’-OMe, so the 5’-site can never be exposed using our 
approach. Thus, if G4498 were fully methylated, U4497 would not be detected. Indeed, we did 
not see U4497, indicating G4498 may be fully methylated. However, another set of back-to-back 
pairs of 28S sites (U4226 and G4227) were both detected with high confidence. The most 
probable explanation for our results is that G4227 is only partially methylated, with the 
unmethylated population allowing the exposure of U4226 (Table 4). This result is consistent with 
the data obtained using Ribometh-seq as well as observations of fractional methylation from 
primer extension experiments (Maden 1986; Krogh et al. 2016). Such patterns prompted us to 
consider the possibility that annotated 2’-O-methylation sites not detected by our method may be 
the result of a complete lack of methylation. To test this possibility, radioactive primer extension 
with low dNTP concentration was used to examine the only missing site in 18S, U1668. As 
expected, a stop corresponding to that modification site was not detected (Figure 15). It is 
interesting to note that this site was also not detected using Ribometh-seq in HeLa cells (Krogh 
et al. 2016). Further evidence from more cell lines will be required to confirm whether this site is 
actually modified in other cells or tissues. 
 
 
Figure 14. Volcano plot of the –log10 p value vs log2 fold change.  
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Each dot represents a single base position in 18S and 28S rRNAs. Base positions are artificially 
filtered by p values and log2 fold changes and color coded. Red dots represent positions with 
log2 fold change <= 7 and adjust p value > 10e-7. Teal dots represent log2 fold change <= 7 and 
adjust p value < 10e-7. Green dots represent log2 fold change > 7 and adjust p value > 10e-7. 
Finally, purple dots represent log2 fold change > 7 and adjust p value < 10e-7. positions labeled 
with purple are determined as high confidence sites. Zoomed in view for two regions are 
examples to show the actual sites the dots represent. Volcano plot was plotted using R package 
ggplot2. The dashed red lines indicate manually set cutoffs. 
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Figure 15. Radioactive dNTP concentration dependent primer extension experiment.  
The primer extension is performed for three selected sites for RibOxi-seq: positive control at 
LSU C1880 (lanes 1 and 2), known but not detected SSU U1668 (lanes 4 and 5) and newly 
detected and not previously known LSU A3717 (lanes 6 and 7). First lane of each set is negative 
control where primer extension is performed with regular dNTP concentration. Second lane of 
each set is performed at low dNTP concentration to allow capture of extension stoppage. 
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3. RibOxi-seq requires modest input material but not high sequencing depth.  
Accurate determination of sites of 2’-OMe using RibOxi-seq relies not only on peak 
calling of oxidized samples, but also on statistical comparison of signals between oxidized and 
control lanes. An initial pilot experiment using a small quantity of total RNA in combination 
with Illumina MiSeq sequencing generated ∼2.5 million reads for each sample (note: the actual 
number of aligned reads was much lower). Upon examining alignment with 3’-end only 
reporting, the pattern was strikingly consistent between experiments, with known sites across 
18S and 28S rRNAs represented by strong peaks in oxidized samples with corresponding gaps in 
control samples mapping to the known sites. After single-base differential expression analysis, 
36/40 sites in 18S and 54/66 sites in 28S were detected using a filtering strategy similar to that 
described above. However, there were also more than 30 new sites detected (Data not shown). 
Those were likely false positives owing to a lack of enough total available control sample 3’-
base counting reads for DESeq2 statistical analysis. Thus, while promising, this pilot experiment 
was not good enough for accurate peak calling. In our experience, highly sensitive and accurate 
site detection is achievable at ∼12 million reads (sequencer output) per sample. 
4. RibOxi-seq is sensitive to methylation changes that are induced by complete depletion 
of specific snoRNA guides. 
 To validate that our method is sensitive to methylation changes, we performed RibOxi-
seq on 293T RNA with snoRNA U63 KD. Although U63 directs methylation on 28S rRNA at 
position 4541 A, we found no major differences in the methylation status between PA1 and 293T 
cell lines. We speculated that this is because KD experiments do not completely deplete 
snoRNAs, and it is possible that a small fraction of the total amount is capable of directing 
normal levels of methylation. We then sequenced additional samples with either U32 snoRNA 
89 
 
KO or U32+U51 snoRNA DKO. U32 is known to direct methylation at both positions 18S 
G1328 and 28S A1523, while U51 is known for 28S A1523. Consistently, no 2’-OMe signals 
were detected at 18S G1328 for U32 KO sample, and 28S A1523 signal is retained. When both 
snoRNAs were knocked out, neither site was detected by RibOxi-seq (Figure 16). these results 
confirm the robustness of Riboxi-seq in detecting 2’-OMe sites. 
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Figure 16. RibOxi-seq on snoRNA KO 293 total RNA samples.  
Track 1 vs. track 2 vs. track 3 vs. track 4. On 18S rRNA, track 1 represents WT sample and has a 
strong 2’-OMe peak at position 1328. U32KO and both double KO sample lost that peak.  
Track 5 vs. track 6 vs. track 7 vs. track 8. On 28S rRNA, track 5 represents WT sample and has a 
strong 2’-OMe peak at position 1523. U32KO also has the same peak present. Both DKO 
samples lost the peak. 
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E. Discussion 
Here we have demonstrated that the principle of using Sodium Periodate to enrich 2’-OMe 
sites are feasible. By coupling the chemistry with Illumina RNA sequencing, we successfully 
developed a highly sensitive and accurate method to profile 2’-OMe. The wide applicability as 
evidenced in experiments using multiple cell lines makes it suitable for both explorative and non-
quantitative validation purposes. We verified that the method is sensitive to methylation status 
changes through snoRNA KOs, and even showed RibOxi-seq’s capability of detecting 
methylation variabilities within a cell line.  
Ribose methylation occurs on average about 1 in every 60 nucleotides in 28S and 18S rRNA. 
Under such conditions, one round of β-elimination is sufficient for accurate site detection even at 
low sequencing depth. However, the occurrence of methylation is very likely to be far lower in 
other RNAs such as lncRNAs and mRNAs, and no instances of this modification have been 
reported so far in human, other than in 5’-cap structures. In order to detect mRNA modifications, 
not only will higher sequencing coverage be required, but also perhaps multiple β-elimination 
steps to greatly increase the probability of 3’-end 2’-OMe exposure. Also, additional β-
elimination can be used on rRNAs if the amount of input total RNA (∼7.5 µg per sample) 
described in the standard protocol is impossible to obtain. The required starting material can be 
divided by 2–4 for each round of β-elimination added. 
Several limitations still exist. Although the number of sequencing reads required is 
significantly lower than that for Ribometh-seq, the input RNA material required is in general 
somewhat higher, at the micrograms level, with the possibility of reduction to a sub-microgram 
level if using additional β-elimination steps. Also, as described above, owing to the nature of 
ribose methylated bases being resistant to nuclease and alkaline hydrolysis, it is difficult to detect 
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adjacent modified bases if the distal base is fully methylated. Further, exposure of methylated 
bases relies on extensive and random digestion. tRNAs and other RNAs shorter than 100 bp are 
difficult to study because the sizes of fragments that would need to be generated might be quite 
small and difficult to examine. Finally, the method at the current stage cannot be used as a 
quantitative tool to compare methylation intensity between different sites, since linker ligation 
efficiencies using T4 RNA ligases 1 and 2 have been described to have sequence biases (Raabe 
et al. 2014). Hence, without first determining ligation efficiencies of linkers to each of A, U, C, 
and G bases using spike-ins of known 2’-O-methylated oligos as internal controls, comparisons 
between different sites is not yet possible. On the other hand, comparison between different 
samples at the same site appears to be feasible. 
F. Complete protocol 
The library preparation using our standard protocol requires around 4–6 days to complete with a 
moderate work load, factoring out optimization steps. However, the procedure can be stopped 
whenever an ethanol precipitation is performed and the sample is resuspended into nuclease-free 
water. Alternatively, samples can also be left precipitating in 100% EtOH under −20°C 
indefinitely to increase yield.  
RNA extraction 
For cells cultured in 10 cm Petri dishes, a PureLink RNA Mini Kit is used in conjunction with 
the PureLink on-column DNase set to isolate RNA and remove genomic DNA. Steps for the 
extraction are detailed in the Purelink Kit's protocol. In case any overexpression system is used, 
additional post-extraction gDNA removal may be necessary due to an increase in DNA molarity. 
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The TURBO DNA-free Kit has proven effective for such conditions after following its 
“Rigorous DNase treatment” protocol. 
1. Extract total RNA using the PureLink RNA Mini Kit with PureLink on-column DNase. 
2. Optional: Use the Turbo DNase Kit to further remove contaminating DNA. 
RNA fragmentation 
Each sample set should have at least one control and one oxidation sample. We recommend a 
minimum of three technical replicates for each. After completing fragmentation and the 
subsequent two steps until just before the oxidation procedure, the RNA loss should be ∼40%. It 
is recommended to use an initial total RNA amount of 30 µg (can be lowered upon further 
optimization), which will yield about 18 µg of fragmented RNA (results may vary for each 
laboratory). The amount of fragmented RNA recommended for oxidation is 4–6 µg, and 1 µg for 
nonoxidation. Three technical replicates for all samples require about 15 µg total. The amount of 
starting RNA can be significantly lowered if using the alternative procedure during oxidation and 
β-elimination steps. Such an alternative is also necessary if applying the method on other 
samples depleted of rRNAs.  
3. In a 1.5 mL Eppendorf tube, dilute 15 µg of total RNA (for each sample) into 133.5 µL with 
nuclease-free H2O. 
4. Vortex the mixture and spin for a brief second to collect all liquid at the bottom. 
5. Place the tube into a 90°C heat block for 3 min to denature the RNA and immediately place on 
ice for at least 1 min. 
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6. Dilute 1 µL stock Benzonase (341 U/µL) into 500 U/mL using 681 µL of 1× Benzonase 
buffer. (Always dilute fresh prior to using. Do not freeze.) 
7. Add 15 µL of 10× Benzonase buffer and 1.5 µL of diluted Benzonase to the diluted RNA 
(final RNA concentration: 100 ng/µL). Incubate on ice for 90 min. (This incubation time only 
serves as a starting reference since it can greatly vary between different laboratories. Perform a 
time-course experiment to establish optimal incubation time based on desired fragment length.) 
8. Perform phenol–chloroform extraction. Add 150 µL acid phenol:chloroform and vortex for 10 
sec. Centrifuge at 20,000g at RT for 5 min. 
9. Transfer about ~150 µL of the supernatant into a new set of 1.5 mL Eppendorf tubes. 
10. Ethanol precipitate the RNA. Add 30 µL of 3 M sodium acetate (0.1× volume), 120 µL 
water. Mix well and add 750 µL of 100% ethanol (2.5× volume). 
11. Mix well and place on ice for >30 min to precipitate RNA. 
12. Spin at max (>16,000g) at 4°C or RT for ∼30 min. 
13. Carefully remove the ethanol without dislodging the pellet. 
14. Add ≥500 µL 70% ethanol, vortex, and centrifuge for 10 min to wash the pellet. 
15. Carefully remove the ethanol and air dry the pellet for 2 min. 
16. Resuspend pellet in 100 µL of nuclease-free H2O. 
17. Optional: Examine fragmented RNA size distribution using TapeStation 2200 and RNA 
Screen Tapes. Ensure the pattern has a strong peak spanning the region from 50 to 200 bp. For 
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poly A + samples, it is recommended to increase digestion strength to shift the peak toward even 
smaller sizes. 
18. Ethanol precipitate 5–6 µg fragmented RNA of each sample replicate. 
Oxidation 
To prepare the fragmented RNAs for subsequent elimination of the 3’-end bases to expose ribose 
methylated bases that are potentially positioned one base upstream, these ends need to be 
oxidized into dialdehydes using NaIO4. 
19. Freshly prepare 200 mM NaIO4 solution by dissolving 42.78 mg of the NaIO4 powder per 1 
mL oxidation buffer. Protect the solution from light. Important: This step should be performed 
while precipitating the fragmented RNA and not earlier. 
20. Dissolve RNA pellet in 30 µL oxidation buffer (make sure the pellet is well resuspended) and 
add 10 µL of prepared NaIO4 solution. Mix well and incubate at room temperature protected 
from light for 45 min (briefly vortex and spin the reaction tube every 15 min to ensure proper 
resuspension of the pellet). 
21. Adjust the volume to 90 µL with nuclease-free H2O. Add 10 µL H2O and 1 µL LPA. 
22. Perform ethanol precipitation. Important: After adding 100% ethanol for precipitation and 
centrifugation, white precipitates/film might be seen scattered on the Eppendorf tube wall due to 
high salt content and a typical pellet might not be visible. This is normal. RNA can be recovered 
if the orientation of the tube is kept consistent and a pipettor is used to vigorously flush and/or 
gently scrap the precipitates/film off the wall after adding elimination buffer. 
β-Elimination 
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This step catalyzes the leaving of the 3’-end oxidized base to expose potentially 2’-O-methylated 
bases at the 3’-end of the fragments. 
23. Add 50 µL of β-elimination buffer to dissolve the pellet. Vigorously vortex, pipette up and 
down, or invert the tube to further resuspend the oxidized RNA. 
24. Spin the tubes briefly and transfer samples into PCR strip tubes. Tubes with individual caps 
are highly recommended to prevent cross-contamination, especially in later steps where control 
samples are handled alongside oxidation samples. 
25. Using a thermal cycler, incubate at 45°C for 85 min. 
26. Process samples through NucAway spin columns to remove unwanted small fragments and 
salts from the samples (β-elimination alkaline conditions which can generate small undesirable 
fragments). 
27. Transfer samples into a new set of 1.5 mL Eppendorf tubes. 
28. Ethanol precipitate and resuspend in 22 µL H2O as in the previous oxidation step. Adding 
additional 0.5 µL LPA is highly recommended. 
Phosphate removal and oxidation 
To oxidize all 3’-ends that are not 2’-O-methylated, another NaIO4 treatment is needed. 
However, after β-elimination, RNA fragment 3’-ends will contain a mixture of 3’-phosphates, 
2’-phosphates, and/or 2’-3’-phosphates. It is vital to remove these phosphate groups to avoid 
false positives in the final data representation. T4 PNK is used to remove all three types of 
phosphates. 
29. Transfer to PCR tubes. 
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30. Remove 3’-, 2’-, and 2’–3’-cyclic phosphate using T4 PNK. (Important: The PNK buffer 
used must not contain ATP.)  
31. Incubate at 37°C for at least 4 h (longer incubation times may be OK and might be beneficial 
as T4 PNK is an inefficient phosphatase). 
32. Important: here is where control and oxidized samples are separated. Phenol–chloroform 
extract the dephosphorylated RNA and aliquot 20% of the supernatant for each sample as 
control, while the remaining 80% will go through final oxidation. 
33. Ethanol precipitate controls and resuspend them with 16 µL H2O; at the same time, ethanol 
precipitate oxidation samples into pellets (add 1 µL LPA for both). Store the controls in -80°C. 
34. Freshly prepare 200 mM NaIO4 solution by dissolving 42.78 mg of the NaIO4 powder in 1 
mL oxidation buffer. Protect the solution from light. 
35. Dissolve the RNA pellet from oxidation samples thoroughly in 30 µL oxidation buffer. 
36. Add 10 µL of prepared NaIO4 solution. Mix well and incubate at room temperature protected 
from light for 45 min. 
37. Transfer to a new 1.5 mL Eppendorf tube and ethanol precipitate RNA and resuspend in 16 
µL H2O. If white precipitates remain in the solution, do not remove them. 
38. Following these steps, the samples are properly oxidized. 
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3’ DNA linker ligation 
Ligation of 3’ linkers to unoxidized RNA 3’-ends will enable selective reverse transcription and 
thus, enrichment of 2’-O-methylated RNA fragments. From this step on, control samples will be 
subjected to the exact same procedures. 
39. Thaw the control samples. Transfer 8 µL for each sample into PCR tubes. 
40. Transfer 8 µL of each 16 µL oxidized sample into PCR tubes. Store the remaining 8 µL of 
both control and oxidation for each sample at −80°C as backup. 
41. Ligation of 3’ linker (prepare the reagents in a way that can be properly mixed, as the amount 
of PEG 8000 added can make it difficult).  
42. Incubate the reaction in thermal cycler at 16°C overnight for 18 h. 
Anneal RT primer 
Any 3’ linker not ligated in the previous step will still be freely available for ligation in the 
samples. To ensure the 5’ RNA linker ligation attaches the RNA linkers to sample RNA 
fragments but not to the free 3’ linkers during the next step, the RT primer is annealed first. 
43. Add 1 µL of the 50 µM RT primer and 69 µL nuclease-free water to each sample. 
44. Incubate in thermal cycler with the following program: 
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90°C for 2 min 
65°C for 10 min 
4°C for 1 min 
45. Phenol–chloroform extract and ethanol precipitate (add 1 µL of LPA) each sample and 
resuspend in 11 µL H2O. 
5’ RNA linker ligation 
The double-stranded structures resulting from annealing the RT primers and free 3’ linkers will 
prevent them from being ligated to the 5’ RNA linkers (Munafó and Robb 2010). 
46. Thaw 50 µM RNA linker from −80°C and transfer (number of samples) *1.3 µL into a PCR 
tube. 
47. Denature RNA linker at 72°C for 2 min and return to ice. 
48. Prepare the following ligation reaction.  
49. Incubate at 25°C for 1 h, then terminate reaction at 65°C for 15 min. 
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Reverse transcription 
Because the RT primer has been annealed in the previous step, the RT reaction can proceed 
without addition of primer. During this step, cDNA is synthesized. At the same time, random-
hexamer sequences built into the RT primer are also incorporated into the cDNA library. These 
will allow the removal of PCR duplicates later during data treatment. 
50. Prepare RT reactions to generate a cDNA library using the following setup with SuperScript 
III included reagents.  
51. Incubate the reactions in thermal cycler following the kit's protocol. 
52. Hydrolyze remaining RNAs by adding 4.4 µL of 1 N NaOH and incubate at 98°C for 20 min. 
53. Add 22 µL 200 mM Tris-HCl PH = 7.0 to neutralize the PH. 
54. Use Ampure XP beads at 0.8:1 ratio (add 53 µL Ampure XP solution). Incubate for 5 min to 
let beads bind cDNA of sizes 250 bp and above. 
55. Transfer supernatant to new tubes (discard beads) and add an additional 67 µL Ampure XP 
solution to make the ratio 1:1.8. Finish Ampure XP purification. 
56. Elute using EB buffer. 
PCR amplification of cDNA library 
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Illumina i5 and i7 PCR primer sequences have sequences complementary to the 5’ RNA linker 
and RT primer sequences. This allows direct PCR amplification of the cDNA library. Periodate 
oxidation enrichment in previous steps results in a cDNA library of very low complexity. Hence 
it necessitates additional amplification cycles compared to construction of other types of 
sequencing libraries (∼35 cycles versus ∼12 cycles). The strandedness of the final library is 
second-strand similar to the library prepared using the Illumina ligation method.  
57. Prepare NEB Q5 PCR reactions.  
58. Incubate in the thermal cycler using the following program modified from the Q5 protocol. e 
library prepared using the Illumina ligation method.  
59. Add 25 µL of AmpureXP to achieve a 1:1 ratio to select for fragment of sizes ∼200 bp and 
above, reducing the amount of non-insert fragments (Illumina i5 sequence: ∼70 bp, Illumina i7 
sequence: ∼66, total non-insert product: ∼136 bp). 
60. Purify libraries following the AmpureXP protocol. Resuspend each sample in 15 µL with 
Illumina RSB (resuspension buffer). 
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Library quantification 
61. Use TapeStation and DNA Screen Tape to visualize library size distributions. It should have 
a distribution around 200 bp. Even though stringent steps have been taken to avoid non-insert 
PCR products, they may still be present and are expected. 
62. Accurately measure library concentrations using the Qbit Fluorometer and dsDNA High 
Sensitivity Reagent Kit (follow Qbit protocol). 
63. Calculate library molarity using sizes and concentrations measured. 
Sequencing 
The NextSeq 500 (or MiSeq) 150 cycle Mid Output Kit is used in this experiment with 75 bp by 
75 bp configuration. 
64. Prepare and load the libraries for the NextSeq 500 sequencer following the established 
protocol. Important: Make sure PhiX phage DNA comprises at least 30% of the total library if 
the Riboxi-seq samples are the only samples being sequenced because of the nature of extremely 
low diversity amplicon sequencing. The final loading concentration used in this experiment is 
1.5 pM, which is slightly lower than the 1.8 pM from the protocol. 
Data treatment 
65. Remove read-through sequences. Because of the nature of the sequencing library preparation, 
many fragments will have insert sizes significantly smaller than the 75 bp length sequenced by 
the sequencer. The resulting read-through sequences will greatly impact alignment reliability. 
Cutadapt (Martin 2011), a Python package, is used to first remove read-through sequences at the 
3’-end for both read 1 and read 2. An in-house script has been used to compare randomer 
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sequences and ∼5 bp RNA sequences to determine and collapse PCR duplicates on read 2. 
Finally, we used cutadapt to remove the randomers and linker sequence from 5’-ends of read 2. 
The resulting “.fastq” files can then be used for alignment. 
66. TopHat2 is used to align the reads. The annotation file used consists of chrUn coordinates, 
which contain two sets of 18S and 28S rRNAs, extracted from the hg19 index (Kim et al. 2013). 
67. The “accepted_hits.bam” for each sample are sorted using SAMtools and converted to 
“.BED” files using BEDtools (Heng et al. 2009; Quinlan and Hall 2010). 
68. The third column of the “.BED” file represents the starting and ending positions (with respect 
to 5’- and 3’-ends) of each read, while the sixth column indicates sense or anti-sense. We 
counted the number of reads with 3’-end alignment for each position corresponding to 18S and 
28S rRNA and generated a count table for each sample (only sense reads are taken, since the two 
rRNAs we aligned to the reference sequence were transcribed from the sense strand). 
69. The count data files were then imported into DESeq2 for differential analysis per base 
position (Love et al. 2014). 
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All raw and processed data produced from studies in this chapter II were deposited at the NCBI 
Gene Expression Omnibus (GEO) with accession number: GSE96999. 
All raw and processed data pertaining to T. brucei RibOxi-seq produced from experiments in 
chapter III were deposited at the NCBI Gene Expression Omnibus (GEO) with accession 
number: GSE102516 pending availability of corresponding publication. 
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Chapter III 
Application and Extension of RibOxi-seq 
A. Abstract 
The successful development of the RibOxi-seq provides us the foundation of an accurate, 
robust and cost-effective way to studying 2’-OMe on rRNAs. Although from an evolutionary 
perspective, T. brucei is very distant from human within the Eukarya domain, the conservation of 
2’-OMe machineries is an interesting observation. Although there have been a large number of 
snoRNAs identified, as well as bioinformatically predicted corresponding 2’-OMe sites on T. 
brucei’s rRNAs, the number of experimentally validated sites remains much smaller. Besides the 
field of epitranscriptomics gaining attraction, more evidence suggests an increasing importance 
of 2’-OMe in different life stages of T. brucei. Therefore, we sought to profile 2’-OMe 
landscapes of different stages of the organism to help better understanding the biology of its 
lifecycle and to further highlight the power and potential of RibOxi-seq. In addition, we would 
like to be able to answer the questions asked in Chapter I such as: are there internal 2’-OMe sites 
within mRNAs and can we identify targets for orphan snoRNAs? We performed pilot 
experiment on mouse mRNA, as well as human ESC WT mRNA and SNORD116 KO mRNA. 
In both human and mouse, RibOxi-seq suggests a strong likelihood of detecting 2’-OMe sites, 
pending validation with an independent method, and shows interesting patterning of the 
modification distribution. With some technical difficulties still present, we are still actively 
exploring ways to analyze and compare WT and KO data. 
B. Background 
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Trypanosomes. T. brucei is a protistan parasite causing deadly disease in sub-Saharan 
Africa. During its life cycle the parasite shuttles between its tsetse fly vector and human host 
where it lives freely in the bloodstream. For a rather small genome (35Mb haploid vs. human: 
3200Mb diploid), trypanosomes encode a large repertoire of snoRNAs.  (Schultz et al. 2006, 
Uliel et al. 2004). Although there have been continuous efforts made to map sites of 2’-OMe in 
trypanosomes, only a few laboratories around the world have pursued RNA modifications study 
in parasitic organisms. Over the years, evidence for individual sites slowly accumulated mainly 
contributed by targeted primer extension studies; however, a lack of curated reports or databases 
documenting known sites that are experimentally validated renders 2’-OMe patterns in T. brucei 
and related organisms elusive. Currently, more than 20 snoRNA clusters encoding more than 50 
Box C/D snoRNAs have been identified in transcriptomic studies, suggesting a capability of 
modifying more than 130 sites in rRNA alone. A significant portion of these 130 sites, unlike 
human counterparts, are bioinformatically predicted rather than exhaustively validated (Liang et 
al. 2005, Uliel et al. 2004, Barth et al. 2008).  
 Interestingly, a recent semi-large-scale primer extension study revealed the possibility of 
differential 2’-OMe patterns between the mammalian-infective bloodstream and insect-stage 
procyclic forms (BF and PF) of T. brucei (reviewed in Ponte-Sucre 2016). The detection of 
methylation level changes in certain sites, rather than a change in overall methylation levels, 
provided evidence for possible functional involvement of 2’-OMe in the life cycle of the parasite 
(Barth et al. 2008). With the opportunity to form a close collaboration with Dr. Arthur Günzl’s 
lab within our department as well as the Günzl lab’s collaborators who are experts in 
Trypanosome 2’-OMe, we decided that it would be appropriate and feasible to determine and 
compare rRNA 2’-OMe profiles between T. brucei life cycle stages.  
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Mammalian sites of 2’-O methylation. In Chapter II, I discussed that if we want to adapt 
RibOxi-seq for detection of low abundance transcripts, such as mRNAs, additional rounds of β-
elimination would likely be necessary. However, each round involves several hours of work. We 
alternatively speculated that if we simply increased digestion time length, the odds of sites on 
mRNAs being exposed should increase. Even though there will be significant potential loss on 
number of sites that could have been detected with extra β-elimination, this pilot study only 
serves as proof-of-principle that there are mRNA internal 2’-OMe and that they can be detected 
by RibOxi-seq. 
Introns of ribosomal protein L13a (Rpl13a) codes for a group of snoRNAs including U32a, 
U33, U34 and U35a, whose rRNA targets have been known. Interestingly, snoRNAs from the 
Rpl13a locus are critical regulators of reactive oxygen species and oxidative stress (Michel et al. 
2011, Lee et al. 2016). In an animal model of diabetes from drug-induced beta cell injury, 
genetic loss of the Rpl13a snoRNAs (-/-) reduces oxidative stress, confers partial resistance to 
development of diabetes, and also leads to recovery from injury beta-cell injury with 
normalization of blood glucose over time. Although box C/D snoRNAs were not previously 
known to target mRNA for modification, the Holley Lab has shown preliminary data that these 
snoRNAs might target mRNA for 2’-OMe modification as a novel mechanism of action (Holley 
et al. 2015, Holley lab unpublished data). Therefore, we formed a collaboration in the hope of 
finding direct evidence for the methylation on mRNA and gaining insights on clinical relevance 
of 2’-OMe.  
SNORD116 is a box C/D snoRNA cluster residing within chromosome 15 q11-q13 region. 
There are 30 similar snoRNAs encoded by the cluster (Cavaillé et al. 2000). Prader-Willi 
syndrome (PWS) is a genetic disorder resulted from certain deletions within the region. PWS 
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disrupts normal functions of hypothalamus neurons, including abnormal hormone levels 
(reviewed in Cassidy et al. 2012). However, the underlying molecular basis of the disease is not 
well understood. The locus contains several genes, although interestingly, SNORD116 deletion 
always accompanies PWS patients (Bieth et al. 2015). Thus, the 2’-OMe aspect of the disease 
have not been explored as the SNORD116 cluster snoRNAs are orphan snoRNAs that lack 
known targets. Thus, we would like to investigate whether the SNORD116 snoRNAs have 2’-O-
methylation targets and whether the methylation process is involved in the pathology by 
investigating human 2’-OMe patterns transcriptome-wide.  
C. Methods and Materials 
1. RNA extraction and PolyA RNA isolation 
Total RNA from axenic T. brucei cultures (both BF and PF were cultured in Günzl lab) were 
prepared using PureLink® RNA Mini Kit following manufacturer’s protocol (with on-column 
DNAse treatment). Total RNAs from U32KO/WT mice livers were supplied by Holley lab from 
Duke University. SNORD116 KO/WT H9 human embryonic cell lines were provided by 
Michael Chung from the Chamberlain lab, and RNA extractions were performed using 
PureLink® RNA Mini Kit. mRNAs were enriched for mouse and H9 samples using 
PolyATtract® mRNA Isolation Systems from Promega. 
2. RibOxi-seq 
Standard RibOxi-seq was performed on both T. brucei PF vs. BF total RNA samples, and H9 
SNORD116 WT vs. KO total RNA samples with 2 biological replicates each. RibOxiseq-seq 
protocol was slightly modified in order to improve possibilities for mRNA-site detection. The 
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modified protocol was performed on the following sample sets with 2 biological replicates each: 
mouse U32 WT vs. KO mRNAs; and human H9 SNORD116 WT vs. KO mRNAs. 
D. Results 
1. Profiling of T. brucei 2’-OMe rRNA landscape supports life stage-specific and site-
specific differential methylation 
As mentioned earlier, there has been no curation of experimentally validated T. brucei 2’-
OMe sites for rRNAs to date. However, snoRNA repertoire has been extensively examined, 
which also generated a number of 2’-OMe predictions (Michaeli et al. 2012). Currently, Dr. 
Shulamit Michaeli’s lab (one of our collaborators), is consolidating evidence of Trypanosome 
rRNA 2’-OMe from various sources including bioinformatic predictions, targeted primer 
extension experiments, structural studies, 2’-OMe-seq and known snoRNAs. The goal is to cross 
check between different 2’-OMe detection methods and corresponding snoRNAs. Eventually, 
each position will be evaluated based on cumulative evidence and a cutoff will be set for 
determination of the methylation status. Since RibOxi-seq performed very well on human rRNA 
site-detection, we were optimistic about its potential contribution to this collaborative effort.  
Overall 2’-OMe patterns generated through RibOxi-seq between the two life stages are 
remarkably similar when visualized on the IGV genome browser (Figure 17A). Interestingly, 
after filtering the DESeq2 statistical analysis output list with adjusted p-value<0.000001 and 
log2 fold change>6, we observed highly comparable high-confidence sites between the two life 
stages with minor differential methylation (Figure 17B). When comparing to data in the lists 
currently being compiled as well as the data from MIchaeli et al. (2012), our results 
experimentally confirmed many of the predicted sites, while validated known sites in a single 
experiment (Table 8). One interesting observation we made comparing to the compiled data was 
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that many sites, which are both validated and detected by RibOxi-seq, showed no evidence in 
existing bioinformatic predictions, underscoring the limitations of algorithms of current tools. 
When compared to 2’-OMe-seq data, there are a number of agreements and disagreements. 
However, we argue that our method should represent a rather accurate picture of the 2’-OMe 
sites because the principle of the chemistry of our approach. Regardless, there are a few 
candidates that received strong scoring for being potential sites and which are differentially 
methylated between life stage differences and worth following up using independent approaches 
(Table 5). How relevant and important differential methylation is on these sites is for T. brucei 
biology will require further investigation.  
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Figure 17. RibOxi-seq on T. brucei BF and PF total RNA samples.  
(A) Visualization of read alignment of RibOxi-seq data for both BF and PF. Region selected is 
18S rRNA region. Genome build is Tb427. Each track represents 2’-OMe patterns of the two 
replicates of the BF and PF respectively. 
(B) After statistical analysis, example of sites that have significant differential methylation 
observations. Purple peaks represent positions that have log2 fold change of greater than or 
equal to 6, while adjusted p value is less than 10e-7; Blue peaks represent positions that have 
log2 fold change of less than 6, while adjusted p value is less than 10e-7; And Blue peaks 
represent positions that have log2 fold change of greater than 6, while adjusted p value is 
greater than 10e-7. In general, only the purple positions are considered once cutoffs are set. 
Here we selected a few sites that are differentially detected between the two life cycle forms. 
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Table 5. List of promising differentially methylated sites in T. brucei to follow up. 
These sites were confirmed in bioinformatic prediction based on snoRNA sequence, validated 
using primer extension experiment, detected using 2’-OMe-seq, and detected in RibOxi-seq. 
Specifically, RibOxi-seq only detected them in PF samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rRNA 
Base 
position Modification 
Box C/D 
snoRNA Prediction 
Primer 
extension  2'-OMe-seq RibOxiseq 
LSU5 1742 Um TB7Cs2C1 Yes ? Yes 
Yes, PF 
Only 
LSU5 916 Um TB11Cs4C2 Yes Y Yes 
Yes, PF 
Only 
LSU3 601 Cm TB10Cs1C1 Yes Y Yes 
Yes, PF 
Only 
LSU3 1264 Cm TB6Cs1C1 Yes ? Yes 
Yes, PF 
Only 
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2. RibOxi-seq can detect mRNA 2’-OMe sites for genes abundantly expressed in 
corresponding cell lines or tissues. 
Our original speculation was multiple extra β-elimination steps would be required. However, 
we were concerned that if starting material is limited, each additional step, which needs to be 
carried out under alkaline conditions and at elevated temperature, could result in accumulation of 
RNA breakages and thus extensive loss of material. We expect occurrences of 2’-OMe sites on 
mRNAs are much less frequent events than on the abundant and highly structured rRNA, which 
could lead to very little material for reverse transcription after oxidation of RibOxi-seq 
procedures. With a low RNA abundance RT reaction, it has been known that strong background 
noise and artefacts can occur (Levesque-Sergerie et al. 2007). Most specifically mis-priming, 
which is resulted from primer partial hybridization with non-specific targets, can generate ‘fake’ 
peaks. In this case, all sequences upstream of detected peaks would appear to contain a motif 
having high to perfect resemblance to part of the RT primer (Gillen et al. 2016). Such patterns 
were evidenced in a methodology, using same principles, that was published the same time as 
RibOxi-seq. Significant mis-priming events consisted of almost 40% of their mRNA sites 
obtained from initial RNA fragments that underwent 13 additional rounds of elimination (Dai et 
al. 2017). Also, total RNA, rather than poly(A)+ RNA, was used in the protocol, leading to the 
possibility of further complications. Interestingly, the corrigendum published later in an attempt 
to address the mis-priming artefact generated data-sets that have no overlap with the original 
published data-sets, even the 60% of sites that reportedly showed little similarity to the 
sequencing primer (https://www.nature.com/articles/nmeth0318-226c). 
To circumvent this potential pitfall, we argue that if we purify poly(A)+ RNAs and perform 
very extensive digestion to increase 2’-OMe exposure after a single step of beta elimination, we 
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may be able to detect at least some sites in mRNAs. Thus, from purified mouse liver poly(A)+ 
RNAs and human H9 poly(A)+ RNAs, we modified the digestion temperature to generate RNA 
fragment pools with an average length of 36bp, while the remaining steps of the RibOxi-seq 
were unchanged (Figure 18). Because rRNAs are highly abundant (making up more than 95% of 
total RNAs), even with poly(A)+ RNA purification, it is inevitable that we still detect rRNA 
sites. Conveniently, this allows us to use the rRNA region as an internal control to ensure the 
RibOxi-seq chemistry worked.  
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Figure 18. New Benzonase digestion optimization for RibOxi-seq.  
Digestion incubation temperature was elevated to room temperature, and incubation time was 20 
minutes. The resulting digestion products are now with sizes averaging 35-40bp long. 
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Our results show that experiments on both mouse and human RNAs are largely consistent 
with known sites in the rRNA region (Figure 19). However, when we examine the data for the 
rest of the transcriptome, we discovered several issues. First, we witnessed variable mis-priming 
events, where observed sites have upstream ‘motifs’ that have 3-8bp matching sequence with the 
RT primer sequence (Figure 20). Our bioinformatic capabilities did not allow us to filter these 
sites out quickly as these are of variable length and some contain regions of base pair 
mismatching. As a consequence, we manually scanned through the genome on the UCSC 
genome browser and recorded non-mis-priming sites. Another type of seeming artifact is the 
occurrence of peak doublets with certain lengths of spacing. When examining UCSC tracks for 
H9 data between a total RNA experiment and a poly(A)+ RNA experiment, we discovered that 
the poly(A)+ RNA experiment detected almost all known sites in the rRNA region. However, 
unlike total RNA data, the poly(A)+ RNA data set also displayed additional peak doublets. When 
we manually filtered out these peaks, total RNA and poly(A)+ RNA data sets became consistent 
with each other.  
Such phenomena suggested that any site that is close to or part of similar doublet peaks are 
best ignored. In the end, we observed several sites that appear to be real sites. Our final list of 
sites in H9 cell corresponds to abundantly expressed genes such as desterin, NOMO family 
genes (NODAL modulators) etc. (Table 9); while mouse datasets generated from liver RNA 
experiment are still under examination, we found genes such as transferrin, a liver specific gene, 
is one of the promising sites after filtering (Figure 21).  
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Figure 19. RibOxi-seq on poly(A)+ enriched mouse liver RNAs and human H9 cell line 
RNAs.  
Top panel is the visual representation of mouse liver 2’-OMe alignment against mm10 genome 
after performing RibOxi-seq. results between biological replicates are highly consistent with 
each other. By comparing our site detection with snOPY database reveals that our method can 
confidently detect mouse 2’-OMe sites (http://snoopy.med.miyazaki-u.ac.jp/). 
Bottom panel. RibOxi-seq alignment visualization for H9 RNA 2’-OMe 18S rRNA sites.  
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Figure 20. Common artefact occurred during RibOxiseq for transcriptomic 2’-OMe 
mapping.  
Post NaIO4 oxidation only a fraction of terminally methylated RNA fragments remains intact, 
who are then being ligated to a 3’- linker. The ligated linker act as an anchor point for 
subsequent reverse-transcription. Due to extremely low abundance of RNA fragment and 
relatively high concentration of primer oligoes, primer can anneal non-specifically and generate 
RT products. In the figure, the relative position of such artefact is shown. 
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Figure 21. Examples of genes with likely mRNA 2’-OMe sites.  
Oxidized samples have promising peaks in NOMO1 and desterin locus. These are not found to 
be associated with any known chemistry artefact. 
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E. Discussion 
In this chapter, we have demonstrated the applicability of the RibOxi-seq method to rRNAs 
in non-PA1 cell lines and even cells from different organisms. Our results corroborated the 
evidence that methylation status change of specific Trypanosome rRNA 2’-OMe sites between 
two life stages might be regulated individually. However, how and why such differential patterns 
occur will require further investigation. One possible way for organisms like mammals is that 
snoRNAs spliced from introns of host genes can be regulated depending on the host gene 
expression levels, thus achieving cell type-specific snoRNA expression levels and ultimately cell 
type -specific 2’-OMe levels. However, there is no evidence of snoRNAs processed from introns 
of T. brucei genes. Then how are snoRNAs of T. brucei regulated? Since T. brucei snoRNAs are 
transcribed and processed into polycistronic transcripts before maturation, it is likely pertaining 
to post-transcriptional regulation (reviewed in Siegel et al. 2011). 
In trying to adapt RibOxi-seq to poly(A)+ RNAs, we have learned that the protocol likely 
needs to be further tweaked and optimized. It was encouraging to show that we were able to 
detect rRNA sites even with poly(A)+ RNA isolation performed, indicating RibOxi-seq is more 
flexible than originally anticipated in terms of the amount of required starting materials. Based 
on such observations, we thus updated the current working protocol. However, mapping sites on 
mRNAs proved to be more complicated than expected. Although rRNA regions worked well as 
internal controls, potential artifacts and low read counts in the rest of the transcriptomic regions 
in non-oxidized samples makes it difficult control for non-specific sites. Our original goal of 
comparing 2’-OMe sites transcriptome-wide on the WT and SNORD116 snoRNA KO samples 
we have are therefore intractable at this moment. We will need to further test and make 
adaptations to the method in order to achieve such capability. 
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Chapter IV 
Conclusions and Future Directions 
 In summary, we have described in this thesis of successful development of a novel high-
throughput method for detection of 2’-OMe in rRNAs - RibOxi-seq. In addition, we have 
demonstrated wide applicability of the RibOxi-seq through experiments on multiple human cell 
lines, mouse liver cells, and two T.brucei cell types. Through performing RibOxi-seq on human 
cell lines, we showed that rRNA transcripts within the same cell type are not modified identically 
(Refer to explanation in chapter 2 and Table 3). We also showed that a decrease in snoRNA 
levels might not contribute to significant changes in methylation levels. By applying RibOxi-seq 
to T.brucei RNAs and cross confirmation with collaborations, we corroborated the evidence that 
methylation patterns could be life cycle or developmental stage specific. In trying to adapt the 
methodology for transcriptome-wide detection, we realized that how the abundance of the 
transcripts remains a hurdle even when purified poly(A)+ RNAs were used. However, after 
efforts to filter out possible artifacts, we produced a list of sites that could prove to be real sites, 
suggesting that we could still achieve transcriptome-wide detection after further optimization of 
each step of the protocol. Overall, the patterns that our candidate sites correspond to abundantly 
expressed genes in any particular cell type indicates the method might be restricted to transcripts 
that are highly expressed. To follow up on the results described in this thesis, two immediate 
aims will be proposed for future investigation of functions of the 2’-O-methylation.  
1. rRNA 2’-OMe landscape profiling of primary cells involved in diseases such as cancers. 
 Are there associations between rRNA methylation abnormalities and diseases? 
rRNAs are most heavily 2’-O-methylated RNA transcripts. Because methylation patterns were 
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shown to vary between different cell types, we speculate such process forms a layer of 
regulation, and thus mis-regulation of such process can contribute to pathogenesis (Figure 17B, 
Table 6, Krogh et al. 2016). To test this possibility, we would choose a cancer type, such as 
melanoma. The rationale is that cancer cells are highly proliferative, thus requiring high 
ribosomal capacity, where 2’-OMe mis-regulation is likely to occur. We would like to extract 
total RNA from primary melanoma cells and matching wild type cells and perform RibOxi-seq. 
To achieve statistical validity, we reason that we should obtain maximum number of samples as 
long as cost and sample source allow. The rRNA 2’-OMe sites will be analyzed and compiled for 
examination of whether there are common depletions or enrichments of modifications at certain 
sites.   
2. Strategies to properly adapt RibOxiseq to transcriptome-wide application. 
 Do currently identified mRNA 2’-OMe sites have merit? Validation of 2’-OMe sites 
on low abundance RNAs have been historically difficult as discussed in the previous chapter. 
Primer extension is in general a very sensitive method even for low abundance RNAs, however, 
we do not know the characteristics of primer extension under low dNTP concentration is 
(Raymond 2005). Although, PCR amplification coupled with primer extension has been used in 
several occasions, it is undesirable as it can introduce further noise into the visualization (Holley 
et al. 2015). Conveniently, the seemingly high efficiency of the snoRNP machinery suggests that 
it can have much higher methylation capacity than the normal biological requirement for 
ribosome biogenesis (Figure 22, Newton et al. 2003). Thus, we reason that if we overexpress 
genes that are on our list such as desterin or NOMO1, and perform primer extension with gene 
specific primers, we should see corresponding bands if those sites are indeed real. It is also 
important to determine if these potential methylation sites are guided by any expressed 
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snoRNAs. As small RNA sequencing technology matured over the past years, it is now possible 
to accurately profile box C/D snoRNA expression levels through CLIP-seq with antibody to 
NOP58 protein (Gumienny et al. 2017). Subsequently, the surrounding sequences of the 2’-OMe 
sites can be bioinformatically analyzed against CLIP-seq snoRNA, from the same cellular 
source, results to determine the guide RNAs.  
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Figure 22. Alternative strategy for validating low abundance RNA 2’-OMe.  
Overexpression plasmids are transcribed by RNA Pol II, and the overexpressed transcripts 
undergo same paths as endogenous mRNAs. Thus, if endogenous transcripts are modified with 
2’-OMe, the overexpressed copies, at least a significant amount of them, will have 2’-OMe. This 
can help with detection signal to noise ratio. 
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 Protocol optimizations for the Illumina platform. So far, reaction composition for 
each enzymatic step of the RibOxiseq-protocol after oxidation follows manufacturer’s 
instructions with RNA quantity estimates made from the original sample. Thus, we will perform 
RibOxi-seq library preparation steps until first ligation. We will then use the entire sample to 
quantify RNA fragment average size and molarity to determine optimal reaction condition. We 
will extend such strategy to cover all remaining steps. By using such strategy, we should be able 
to minimize significant amounts of potential artifacts of RibOxi-seq. 
 Modify RibOxi-seq to work with Oxford nanopore direct RNA sequencing. Recently, 
the Minion sequencing platform became widely available. One of the breakthroughs made by 
this platform is the capability of direct RNA sequencing (Garalde et al. 2018). As a consequence, 
the library preparation step consists of just two ligations, removing the necessity of conversion to 
cDNA and PCR amplification. We reason that by adapting RibOxi-seq to the Oxford nanopore 
platform, we would greatly reduce bias and experimental artifact. In addition, the method can 
also become quantitative as the only major variable is ligation efficiency. We will design custom 
oligos so that they can only be ligated to 2’-O methylated ends but not dialdehydes. The oligos 
can be easily designed to be compatible with the new sequencing platform. In principle, there 
appear to be no technical barriers for this adaptation, and we will investigate its validity (Figure 
23). 
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Figure 23. Strategy to adapt RibOxi-seq to Oxford Nanopore direct RNA sequencing.  
The direct RNA sequencing protocol requires two simple ligation steps for conversion of RNA 
of interest into RNA library. The second ligation step is universal, while only the first ligation is 
target specific. The RNA adapter denoted Oligo A/B duplex can be modified to accommodate 
random annealing and ligation instead of AAAAAAAAAA to UUUUUUUUUU annealing.  
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Table 6. List of reagents and equipment used in RibOxi-seq 
 
Reagents 
• Seal-Rite 2.0 mL microcentrifuge tube, natural (USA Scientific, 1620-2720) 
• PA-1 [PA1] cell line (ATCC, CRL-1572) 
• PureLink RNA Mini Kit (Thermo Fisher Scientific, 12183025) 
• PureLink DNase Set (Thermo Fisher Scientific, 12185010) 
• TURBO DNA-free Kit (Thermo Fisher Scientific, AM1907) 
• Ultra-pure Benzonase (Sigma, E826305KU) 
• 10× Benzonase buffer (store at 4°C) 
• 3 M sodium acetate pH = 5.2 
• Ethanol 100% 
• Ethanol 70% 
• UltraPure Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v) (Thermo Fisher Scientific, 
15593031) 
• Acid-Phenol:Chloroform, pH 4.5 (with IAA, 125:24:1) (Thermo Fisher Scientific, 
AM9720) 
• NucAway Spin Columns (Thermo Fisher Scientific, AM10070) 
• RNA Analysis ScreenTape (Agilent, 5067-5576) 
• RNA Analysis ScreenTape reagents (Agilent, 5067-5577) 
• High sensitivity D1000 DNA ScreenTape (Agilent, 5067-5584) 
• High sensitivity D1000 DNA ScreenTape reagents (Agilent, 5067-5585) 
• Linear polyacrylamide 10 µg/µL (Mullins Molecular Retrovirology Lab Short protocol) 
• Sodium meta-periodate (Sigma-Aldrich, 7790-28-5) 
• Sodium periodate oxidation buffer: 4.375 mM sodium borate, 50 mM boric acid, pH = 
8.6 
• 0.2 mL PCR 8-tube FLEX-FREE strip, attached clear flat caps, natural (USA Scientific, 
1402-4700) 
• β-elimination buffer: 33.75 mM sodium borate, 50 mM boric acid, pH = 9.5 
• T4 Polynucleotide Kinase (NEB, M0201L) 
• SUPERase• In RNase Inhibitor 20 U/µL (Thermo Fisher Scientific, AM2696) 
• RNaseOUT Recombinant Ribonuclease Inhibitor (Thermo Fisher Scientific, 10777019) 
• T4 RNA Ligase 2, truncated KQ (NEB, M0373S) 
• T4 RNA Ligase 1 (NEB, M0204S) 
• DMSO 100% 
• SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific, 18080051) 
• Sodium hydroxide 1 N 
• EB buffer: 10 mM Tris-Cl, pH 8.5 
• Q5 High-Fidelity 2× Master Mix (NEB, M0492S) 
• Agencourt AMPure XP, 450 mL (Beckman Coulter Life Sciences, A63882) 
• Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, Q32854) 
• NextSeq 500/550 Mid Output v2 Kit (150 cycles) (Illumina, FC-404-2001) 
• Shrimp alkaline phosphatase (rSAP, NEB, M0371S) 
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Equipment 
Table top centrifuge 
Programmable thermal cycler 
Heat blocks/water baths 
NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, ND-2000) 
2200 TapeStation (Agilent Technologies, G2964AA) 
Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Q32866) 
NextSeq 550 System (Illumina) 
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Table 7. List of primers and other oligos used. 
RibOxi-seq Primers and linkers: 
3′ Preadenylated DNA linker (NEB Universal miRNA Cloning Linker, S1315S, dissolve into 
50 µM) 
• 5′-/rApp/CTGTAGGCACCATCAAT/NH2/-3′ 
5′ RNA linker (50 µM stock) 
• 5′-/Biosg/rArCrArCrGrArCrGrCrUrCrUrUrCrCrGrArUrCrU-3 
Reverse transcription primer (50 µM stock) 
• 5′-
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTRANATTGATGGTGCCTACA
G-3′ 
(Important: The “RAN” represents a customizable random hexamer sequence that can be 
used to remove PCR duplicates later in the data analysis. Random hexamer sequences are 
used in the experiments, but longer is recommended for higher sequencing depth.) 
Illumina compatible barcoded PCR primers 
• i5: 5′-aatgatacggcgaccaccgagatctacacBARCODEacactctttccctacacgacgctcttccgatct-3′ 
• i7: 5′-caagcagaagacggcatacgagatBARCODEgtgactggagttcagacgtgtgctcttccgatct-3′ 
(Barcodes are customizable. The protocol is established using paired-end sequencing with 
dual barcodes. Important: When demultiplexing, the i7 barcode sequence needs to be 
specified as reverse complement to what is in BARCODE). 
It is possible to design longer linker sequences, matching RT primer and PCR primers to 
increase amplification specificity and efficiency. 
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Primers for cDNA validation: 
Forward: 
28S-1 GCTCTCCCACCCCTCCTC 
28S-2 CGCAGGTGCAGATCTTGGT 
Reverse: 
RibOxi-seq RT Primer w/o hexamer: 
 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT ATTGATGGTGCCTACAG 
 
RT primer sequences for radioactive dNTP concentration dependent primer extension: 
LSU C1880 (positive control):                              5’-ATGGCCACCGTCCTGCT-3’ 
SSU U1668 (not detected):                                    5’-ATCCGAGGGCCTCACTA-3’ 
LSU A3717 (Novel):                                              5’-GGCATTTGGCTACCTTA-3’ 
 
Anti-sense oligo (ASO) for U63 snoRNA KD: 
U63_1:                               
mA*mG*mU*mU*mU*T*C*C*A*C*A*C*G*T*T*mC*mU*mU*mU*mC 
U63_2:                                               
mC*mU*mC*mA*mG*T*C*A*T*T*A*G*T*T*T*mU*mC*mC*mA*mC 
Non-specific Control: 
Proprietary scrambled LNA oligo from Exiqon  
 
Primers for U63KD qPCR: 
Forward: 
ATCATTCTGAAAGAACGTGTGG 
Reverse: 
Universal reverse primer from miScript II RT PCR kit 
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Table 8. List of 2'-OMe sites detected in T. brucei using RibOxiseq 
  
5.8S      
Modification Position Predictions Primer extension RibOxi-seq PF RibOxi-seq BF 
Um 7 TB10Cs1C3 N/A No No 
Am 41  N/A Yes Yes 
Am 43 TB10Cs7C3a/b N/A Yes Yes 
Gm 75 TB8Cs3C3 N/A Yes Yes 
Am 163 TB9Cs4C2 N/A Yes Yes 
            
18S      
Modification Position Predictions Primer extension RibOxi-seq PF RibOxi-seq BF 
Cm 16 TB10Cs2C1 N/A No No 
Um 36 TB10Cs2C1 N/A No No 
Cm 46 TB8Cs3C3 N/A No No 
Am 56 TB8Cs2C1 N/A No No 
Um 57  N/A Yes Yes 
Cm 66 TB8Cs2C1 N/A Yes Yes 
Um 123  N/A Yes Yes 
Am 125 TB8Cs1C2 N/A Yes Yes 
Um 386  N/A Yes Yes 
Cm 507  Yes No No 
Cm 668  N/A Yes Yes 
Um 680 TB10Cs3C3 Yes Yes Yes 
Um 714 TB9Cs2C6 N/A Yes Yes 
Am 721 TB6Cs2C1 N/A Yes Yes 
Am 738  N/A Yes Yes 
Am 818   N/A No Yes 
Cm 819  N/A Yes Yes 
Um 977  Yes No No 
Um 996  Yes No No 
Um 999  Yes No No 
Um 1002  Yes No No 
Um 1038  N/A Yes Yes 
Um 1425  N/A Yes Yes 
Gm 1432  N/A Yes Yes 
Um 1433  N/A Yes Yes 
Um 1447  N/A Yes Yes 
Gm 1517 TB11Cs3C2 N/A Yes Yes 
Gm 1531 TB3Cs1C1 N/A Yes Yes 
Gm 1532 TB3Cs1C1 N/A No No 
Gm 1603 TB8Cs3C2 Yes Yes Yes 
Gm 1628  N/A Yes Yes 
142 
 
Um 1630 TB10Cs2"C3 N/A No No 
Um 1652 TB10Cs1C3 Yes Yes Yes 
Um 1674 TB10Cs3C2 N/A Yes Yes 
Gm 1675  N/A Yes Yes 
Gm 1676 TB9Cs3C1 N/A Yes Yes 
Gm 1678  N/A Yes Yes 
Am 1680  N/A Yes Yes 
Gm 1700 TB10Cs2"C1 N/A Yes Yes 
Cm 1758  N/A Yes Yes 
Um 1843  N/A Yes Yes 
Um 1844 TB7Cs1C1 Yes Yes Yes 
Am 1871  N/A Yes Yes 
Cm 1887  Yes No No 
Gm 1895 TB9Cs2C4 N/A Yes Yes 
Um 1899 TB11Cs2C1 Yes Yes Yes 
Gm 1931 TB10Cs4C4 N/A Yes Yes 
Cm 1932 TB10Cs4C2 N/A Yes Yes 
Am 2016  Yes No No 
Am 2050  Yes No No 
Um 2054 TB8Cs2C0 N/A Yes Yes 
Cm 2089  Yes No No 
Am 2096 TB9Cs3C2 Yes Yes Yes 
Cm 2104  Yes No No 
Um 2122  N/A Yes Yes 
Um 2123 TB10Cs4C3 N/A Yes Yes 
Cm 2134 TB10Cs4C3 Yes Yes Yes 
Um 2154  N/A Yes Yes 
Gm 2156  N/A Yes Yes 
Cm 2216  Yes No No 
Gm 2227 TB8Cs1C1 N/A Yes Yes 
            
28S Alpha           
Modification Position Predictions Primer extension RibOxi-seq PF RibOxi-seq BF 
Am 254 TB10Cs3C2 N/A Yes Yes 
Um 306  N/A Yes Yes 
Am 713  N/A Yes Yes 
Am 743 TB9Cs2C2 N/A Yes Yes 
Am 744  N/A Yes Yes 
Am 746 TB10Cs2C2 N/A Yes Yes 
Cm 760 TB9Cs2C2 N/A Yes Yes 
Am 762  N/A Yes Yes 
Gm 880  Yes Yes Yes 
Cm 887   N/A No Yes 
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Cm 912  N/A Yes Yes 
Um 914 TB9Cs2C3 N/A No No 
Gm 915  Yes No No 
Um 916 TB11Cs4C2 Yes Yes No 
Gm 925 TB9Cs2C3 N/A No No 
Am 927 TB11Cs4C2 Yes Yes Yes 
Cm 970  N/A Yes Yes 
Gm 976   N/A No Yes 
Am 986 TB10Cs4C5 N/A No No 
Gm 992  N/A Yes Yes 
Am 996 TB9Cs5C2 N/A Yes Yes 
Gm 998  N/A Yes Yes 
Um 999  N/A Yes Yes 
Cm 1006 TB9Cs5C1 N/A Yes Yes 
Um 1019  N/A Yes Yes 
Am 1024 TB11Cs1C3 N/A Yes Yes 
Gm 1027  N/A Yes Yes 
Gm 1028 TB9Cs2C5 N/A Yes Yes 
Um 1145 TB10Cs3C4 Yes Yes Yes 
Um 1166  N/A Yes Yes 
Am 1179  N/A Yes Yes 
Am 1180 TB9Cs5C1 N/A Yes Yes 
Um 1181 TB10Cs3C4 Yes Yes Yes 
Um 1218  Yes No No 
Um 1229  N/A Yes Yes 
Gm 1267 TB9Cs4C1 N/A Yes Yes 
Um 1330 TB10Cs5C1 N/A Yes Yes 
Gm 1369  Yes No No 
Am 1379  Yes No No 
Am 1391  Yes No No 
Um 1406  Yes No No 
Um 1448 TB8Cs2C2 N/A Yes Yes 
Gm 1572   N/A No Yes 
Gm 1605 TB10Cs2"C3 N/A Yes No 
Cm 1608 TB8Cs3C1 Yes Yes No 
Am 1620 TB8Cs3C1 Yes Yes No 
Gm 1621  N/A Yes Yes 
Gm 1634 TB8Cs1C3 Yes No No 
Gm 1709 TB8Cs1C1 Yes Yes Yes 
Um 1742 TB7Cs2C1 N/A Yes No 
            
28S Beta      
Modification Position Prediction Primer extension RibOxi-seq PF RibOxi-seq BF 
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Gm 71 TB9Cs1C1 N/A No No 
Um 73  N/A Yes Yes 
Am 95 TB3Cs3C1 N/A Yes Yes 
Cm 377 TB9Cs4C3 Yes Yes Yes 
Um 391  Yes No No 
Am 395  N/A Yes Yes 
Am 400 TB6Cs1C2 Yes Yes Yes 
Um 418 TB11Cs2C1 Yes No No 
Am 439  N/A Yes Yes 
Am 520 TB10Cs7C2 N/A Yes Yes 
Am 544  N/A Yes No 
Am 545 TB6Cs1C3 Yes Yes Yes 
Um 546  N/A Yes Yes 
Um 550  N/A Yes Yes 
Gm 552 TB10Cs1C4 Yes Yes Yes 
Um 578 TB11Cs3C1 Yes Yes Yes 
Am 588 TB8Cs1C3 N/A Yes No 
Am 590  N/A Yes Yes 
Um 596  N/A Yes Yes 
Cm 601 TB10Cs1C1 Yes Yes No 
Am 609 TB10Cs1C1 Yes Yes Yes 
Am 621  N/A Yes Yes 
Am 622 TB10Cs2'C1 Yes Yes Yes 
Am 646 TB11Cs4'C1 N/A Yes Yes 
Gm 659 TB9Cs2C7 N/A Yes Yes 
Um 672  Yes No No 
Gm 673 TB11Cs4C3 N/A No No 
Um 685 TB9Cs2C7 Yes Yes Yes 
Um 719 TB10Cs3C5 N/A No No 
Um 728 TB10Cs3C5 N/A Yes No 
Um 729  N/A Yes Yes 
Um 931  N/A Yes No 
Cm 969  N/A No Yes 
Um 1011 TB6Cs1C2 N/A No No 
Gm 1019  N/A No Yes 
Gm 1062 TB11Cs2C1 Yes Yes Yes 
Gm 1094 TB5Cs1C1 N/A Yes Yes 
Um 1098  N/A Yes Yes 
Cm 1175 TB5Cs1C1 N/A Yes Yes 
Am 1201 TB10Cs2"C2 N/A Yes Yes 
Gm 1245 TB3Cs1C-1 Yes Yes Yes 
Gm 1247 TB11Cs1C2 Yes Yes Yes 
Cm 1264 TB6Cs1C1 N/A Yes No 
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Gm 1269 TB11Cs1C2 Yes Yes Yes 
Gm 1293  Yes No No 
Gm 1295  Yes No No 
Cm  1333  Yes No No 
Um 1336  Yes No No 
Gm 1349  Yes No Yes 
Um 1375 TB10Cs3C1 Yes Yes No 
Gm 1376  N/A Yes Yes 
Am 1388 TB11Cs4C1 Yes Yes Yes 
Am 1400 TB11Cs4C1 Yes Yes Yes 
Am 1412  N/A Yes No 
Cm 1413 TB9Cs2C1 N/A Yes Yes 
Um 1429  N/A Yes Yes 
Um 1434  N/A Yes Yes 
Um 1435 TB9Cs3C3 N/A Yes Yes 
Sites detection is summarized from 5.8S, 18S, 28S alpha and 28S beta rRNAs. Detected sites are 
compared with bioinformatic predictions and previous experimental data from Michaeli lab and 
Michaeli et al. (2012). 
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